Economic evaluation of selected finnish screening programmes by Leivo, Tiina
Department of Public Health, University of Helsinki, Finland 
 
 
 
ECONOMIC EVALUATION OF SELECTED  
FINNISH SCREENING PROGRAMMES 
 
 
 
Tiina Leivo 
 
 
 
Academic Dissertation 
To be publicly discussed, by permission of the Medical Faculty of the University of 
Helsinki, in the Auditorium XII in the main building of the University of Helsinki, on 
August 3rd, 2001, at 12 o’clock noon. 
Helsinki 2001 
 
 
 
 
 
 
 
 
 2
Supervised by : 
Professor Harri Sintonen 
Department of Public Health 
University of Helsinki 
and 
Docent Risto Tuominen 
Department of Public Health 
University of Helsinki 
 
Reviewed by: 
Associate Professor Ivar Sonbo Kristiansen 
Institute of Public Health, Health Economics Research Unit 
University of Odense, Denmark 
and 
Docent Pekka Rissanen 
Department of Public Management 
University of Vaasa 
 
Opponent: 
Docent Jouko Isolauri 
Department of Surgery  
Turku University Central Hospital 
 
ISBN 952-91-3614-5 
ISBN 952-10-0066-X (pdf version, available at http://ethesis.helsinki.fi) 
 
Yliopistopaino 
Helsinki 2001 
 
 
 
 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      To Janne, Joel, Julia and Jasmin 
 4
  
 5
CONTENTS          
 
LIST OF ORIGINAL PUBLICATIONS    7 
I INTRODUCTION        9 
II ECONOMIC EVALUATION     13 
III REVIEW OF THE LITERATURE    20 
3.1 Economic evaluation of screening programmes in Finland   20 
3.2 Economic evaluation of ultrasound screening in pregnancy    20 
3.3 Economic evaluation of breast cancer screening      21 
3.4 Economic evaluation of double - reading mammograms    23 
3.5 Economic evaluation of H pylori screening     24 
IV AIMS OF THE STUDY      26 
V MATERIAL AND METHODS     27 
5.1 Effectiveness data (I, II, III)       27 
5.2 Cost data (I, II, III)        30 
5.3 Measure of cost-effectiveness (I, II, III)      32 
5.4 Costs and benefits in cost-benefit analysis (IV)     33 
5.5 Valuation and discounting (I, II, III, IV)      39 
5.6 Sensitivity analysis (I, II, III, IV)       40 
 
VI RESULTS         43 
6.1 Ultrasound screening in pregnancy (I)      43 
6.2 Breast carcinoma screening (II)       44 
6.3 Double-reading mammograms (III)      46 
6.4 Helicobacter pylori screening (IV)      47 
 
 6
VII DISCUSSION        49 
7.1 Material and methods (I, II, III, IV)      49 
7.1.1 Cost-effectiveness-analysis material and methods (I, II, III)   49 
7.1.2 Cost-benefit-analysis material and methods (IV)    51 
7.1.3 Valuation and discounting methods (I, II, III, IV)    53 
7.2 Ultrasound screening in pregnancy (I)      54 
7.3 Breast carcinoma screening (II)       55 
7.4 Double-reading mammograms (III)      57 
7.5 Helicobacter pylori screening (IV)      58 
 
VIII SUMMARY AND CONCLUSIONS    59 
 
APPENDIX 1 CURRENT SCREENING PROGRAMMES IN FINLAND  62 
APPENDIX 2 PROPOSED SCREENING PROGRAMMES IN FINLAND 65 
 
IX ACKNOWLEDGEMENTS      67 
 
X REFERENCES        69 
 7
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following articles, which are referred to in the text by the 
Roman numerals I-IV. 
 
I Leivo T, Tuominen R, Saari-Kemppainen A, Ylöstalo P, Karjalainen O, Heinonen 
O.P.Cost-effectiveness of one-stage ultrasound screening in pregnancy: a report from 
the Helsinki ultrasound trial. Ultrasound Obstet. Gynecol. 1996;7:309-14. 
II Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen O.P.The Cost-
effectiveness of Nationwide Breast Carcinoma Screening, 1987-1992 in Finland, 
1987-1992. Cancer 1999;86:638-46.  
III Leivo T, Salminen T, Sintonen H, Tuominen R, Auerma K, Partanen K, Saari U, 
Hakama M, Heinonen O.P.Incremental Cost-Effectiveness of Double-reading 
Mammograms. Breast Cancer Res. & Treatment. 1999;54:261-7. 
IV Leivo T , Salomaa A , Kosunen T , Tuominen R , Färkkilä M , Linna M, Sintonen 
H. Cost – benefit analysis of Helicobacter pylori screening. Submitted. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 8
 
 9
I INTRODUCTION 
 
In order to optimize the use of scarce resources, economic evaluation of health 
interventions is a necessity highly desirable. From the viewpoint of national economy, 
optimization  leads to more utility per resource unit used. 
 
Economic evaluation is an aid to decision making, but criteria other than efficiency  
may also be relevant when making value judgements as to whether or not to provide a 
particular screening programme. In particular,  concerns of equity, which are not 
formally addressed in most economic analyses, may have an important impact on 
decisions (Brown et al 1998). 
 
Other methods than economic evaluation are in practice often used when choices 
about health interventions are made. Methods based on notions of medical necessity 
or standards of evidence are used. However, these methods often implicitly involve 
both economical and value judgements, but in fact lack the information about costs 
and health consequences (Gold et al 1996 ).  
 
The aim of screening is to detect a disease in preclinical phase to reduce future 
mortality and morbidity.  From a broad perspective a considerable part of health care 
can be defined as preventive. Especially if psychiatric conditions  are also taken into 
account, almost every doctor-patient visit could be defined as preventive. Preventive 
interventions fulfil the requirements of a screening programme, if a specified 
screening programme protocol, including a defined screening test exists. A screening 
test can also be a formulated question sheet to screen for behavioural or psychiatric 
diseases.   
 
An ideal screening programme should have the following medical prerequisites 
(Wilson et al 1968, Hakama et al 1990,Chamberlain 1984,Day et al 1984, Hristova 
1996): 
A disease is suitable for screening if: 
• it is an important health problem justifying the efforts of screening 
• there is a long enough detectable asymptomatic preclinical phase 
• the proportion of lesions found in this preclinical phase that would progress to 
clinical lesions is significant 
• an acceptable treatment is available which can improve a patient’s prognosis 
for the earlier diagnosis 
 
Modifications of these criteria encompass the need of economic evaluation of 
screening programmes in that they recognise the economic costs of the programme 
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have to be considered in relation to the benefits of early detection. Generally accepted 
screening criteria include also (Frame 1986): 
• tests that are acceptable to patients must be available at reasonable cost to 
detect the condition in the asymptomatic period 
• the incidence of the condition must be sufficient to justify the cost of screening 
 
The test should be valid and identify the disease in its preclinical phase. The test 
should be acceptable for the population - easy to apply, painless and without side 
effects. 
A screening programme should have the following features: 
• the target population should be identified 
• individuals in the target population should be identifiable 
• high coverage and attendance rates can be guaranteed 
• there should be facilities for conducting the tests 
• there should be a designed and agreed referral system 
• there should be an organized quality control system 
 
At present, mostly nationwide universal screening programmes are run in Finland. In a 
nationwide programme the target population is identified by age, gender or pregnancy. 
Another option would be to identify the target population by relative risk of morbidity, 
this is less common. 
   
In Finland preventive medicine has been emphasized. As a consequence, relatively 
many nationwide screening programmes are being undertaken. All these programmes 
are free of charge for the attendants according to the principle of equity. The 
attendance rates in all Finnish screening programmes have traditionally been very 
high. At present Finnish nationwide screening programmes include: 
 
1. Antenatal screening 
Finland has a very intensive preventive maternity welfare programme which is 
organised by the local health centres’ maternity counselling clinics. According to the 
national guidelines primiparas should visit the maternity guidance center 13-17 times, 
and multiparas 9-13 times respectively during pregnancy. The antenatal screening 
programme includes several physical, clinical and laboratory screening tests to detect 
pregnancy-induced diseases or disorders, infections, developmental abnormalities and 
malformations. Appendix 1. ( Hiilesmaa et al 2000, Viisainen K 1999, Leinikki et al 
2000 ): 
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2. Perinatal screening 
Perinatal screening is performed in the hospital where the child is born including 
laboratory and clinical examinations. Appendix 1.  
 
3. Child counselling clinic screening 
Under seven-years-old children are offered several child counselling clinic visits 
(Simell et al 1997, Yleislääkärin käsikirja 1994). The child guidance clinic 
programme includes 6 GP visits and around 14-18 nurse visits. The visits include 
guidance, a vaccination programme and numerous specified clinical screening tests. 
Appendix 1. Screening for behavioural or psychological disorders is also 
recommended, but no formal screening tests, i.e. question sheets, are used. 
 
4 Screening in the defensive armed forces 
Finland has a liability to military service. Four physical doctor’s examinations are due 
before and during a term of the service. The aim of the examinations is to define the 
military service class and to prevent morbidity during the service. Appendix 
1.(Lääkärintarkastusohje 1997, Yleislääkärin käsikirja 1994): 
The specified question sheet includes also questions about previously diagnosed 
diseases, which do not fufil the definition for screening.   
 
5 Screening in occupational health care 
Screening in occupational health care is common, although no formal screening 
programmes exist. Most often the routine testing of blood pressure, serum lipids and 
cholesterol, hemoglobin, blood glucos and small blood count take place. 
 
6 Cancer screening 
Finland has two nationwide cancer screening programmes. All 30-60-years-old 
women are invited every fifth year to cervical cancer screening. All 50-59 years-old 
women are invited every second year to breast cancer screening (Teppo et al 2000). 
 
At present, targeted non-nationwide screening is organised for chronically ill patients. 
For example, diabetes mellitus- patients are offered several screening tests during the 
course of the disease. Adenoma – and ulceritis colitis patients are offered targeted 
colorectal cancer colonoscopic screening.   
 
There is continuous pressure from health care professionals and from the public to 
introduce new screening programmes to prevent morbidity and mortality. The health 
care professionals see the possibilities of new technologies. For example, at present 
several hundred genetic diseases could be screened by gene technology (Suomen 
Lääkärilehti, Uutispäivyri 1997). At the level of national economy, it has been 
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observed that the higher an individual’s income, the proportionally higher is their 
expenditure for health care. 
 
Currently in Finland, several new screening programmes are under discussion or in 
their pilot phase (Hiilesmaa et al 2000, Leinikki et al 2000, Teppo et al 2000, 
Saarelma et al 2000, Robinson 1998). Appendix 2. 
 
In this study two nationwide Finnish screening programmes, and one pilot Finnish 
screening programme aimed at nationwide use are subjected to economic evaluation. 
 
In Finland, 65 000 women become pregnant annually. Ultrasound screening in 
pregnancy is used in most Finnish communities aiming at early detection of 
malformation and the subsequent  termination of the pregnancy, if the mother so 
wishes.  
 
Breast carcinoma is the most common cancer affecting the female population in 
Finland. The mean annual number of new cancer cases diagnosed in 1988-1992 was 
2647. (Finnish Cancer Registry 1995) Breast carcinoma screening, covering women 
ages 50-59 years is used nationwide in Finland aiming at the detection of cancer at an 
early and curable stage. The double reading practice of mammograms is the strategy 
actually used in mammography screening in Finland. The double reading practice is 
recommended aiming at better detection rate of cancers within about half of the 
screening programmes internationally (Ballard-Barbash 1999). 
 
Helicobacter pylori infection is typically acquired in childhood. It causes bacterial 
infection of the gastric mucosal surface that causes progressive damage of the 
stomach. The possible clinical manifestations such as peptic ulcer and gastric 
malignancy appear in adulthood.(Axon et al 1997, Blaser 1990). The prevalence of the 
H pylori infection is a cohort- phenomenon, being 80-90% in the cohorts born in the 
beginning of the century and 10-20% in the cohorts born in the 1970’s (Sipponen 
1995).  The infection can be treated with antibiotics. Helicobacter pylori pilot 
screening is used in one Finnish community.  The population – based Vammala  H 
pylori pilot screening study was started in 1994 in Vammala, a semi-urban community 
in South-West Finland. Until the end of 1998, 5288 screenees in the 15 to 45 age 
group have entered the programme (Salomaa et al 1998). 
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II ECONOMIC EVALUATION 
 
Economic evaluation can be defined as the comparative analysis of alternative courses 
of action, e.g., to screen or not to screen, in terms of both their costs and 
consequences. The use of any scarce resources, be they manpower, buildings or 
equipment, has an opportunity cost in terms of the benefits foregone by denying those 
resources to other competing claims. Economics is concerned principally with 
allocating resources efficiently. Efficiency is about making choices, which derive the 
maximum total benefit from the  limited resources available (Drummond 1987, Brown 
et al 1998).   
 
The principal methods for full economic evaluation are: cost-minimization analysis, 
cost-effectiveness analysis, cost-benefit analysis and cost-utility analysis. The 
identification of various types of costs and their subsequent measurement in monetary 
terms is similar across these different evaluation methods. However, the nature of the 
consequences stemming from the alternatives being examined may differ 
considerably. (Drummond 1987).   
 
An economic evaluation through cost-minimization analysis requires that no outcome 
differences exist between the alternatives.  In most circumstances, however, the 
outcomes will differ in some way and then the technique that can consider differences 
in both costs and outcomes is required (Drummond 1987, Brown et al 1998). Cost-
minimization analysis is really a special form of cost-effectiveness analysis, where the 
consequences of the alternative treatments being compared turn out to be equivalent 
(Drummond et al 1997).  
 
Cost-effectiveness analysis requires a single effect of interest, common to both 
alternatives, but achieved to different degrees. The measurement of consequences is in 
natural units, e.g., life years gained. In assessing screening programmes, process 
measures such as the proportion of cases detected are often used as the measure of 
effectiveness. The additional costs and effects of an alternative programme are often 
presented in terms of an incremental cost-effectiveness ratio. In cost-effectiveness 
analysis comparison cannot be  made across health care programmes, where different 
outcome measures are used. Moreover, it is unlikely that all the important outcomes 
are captured by a unidimensional measure of effectiveness (Drummond 1987, Brown 
et al 1998).  
 
In cost-benefit analysis effects can be single or multiple, not necessarily common  to 
both alternatives, and common effects may be achieved to different degrees by the 
alternatives. The measurement of consequences is uniquely in monetary terms. In 
practice complete cost-benefit studies are rarely undertaken to evaluate health care 
programmes, because of the practical difficulty and the social dislike of putting 
monetary values on life and suffering (Drummond 1987, Brown et al 1998). The 
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recent literature contains a number of studies that assess individuals’ willigness to pay 
for health benefits. A comprehensive cost-benefit analysis of health care interventions 
would use this approach to value health benefits. However, very few cost-benefit 
analyses incorporating these estimates have so far been published. (Drummond et al 
1997).  
 
In cost-utility analysis the effects are measured in quality-adjusted life-years gained. It 
provides a broader comparatibility between different programmes than cost-
effectiveness analysis. Programmes can be ranked according to their incremental 
(additional) cost per QALY gained and, in the context of a fixed budget for health 
care, those programs offering additional QALYs at lowest additional cost per QALY 
should be given priority (Drummond 1987, Brown et al 1998).     
 
Economic evaluation is according to Brown et al (1998) particularly relevant to 
screening for a number of reasons. Firstly, screening is discretionary: the case for 
intervention can be relatively dispassionately decided in the light of the probabilistic 
expectation of benefit to a proportion of those screened. Screening is not normally 
subject to the pressures from the social ‘rule of rescue’. Secondly, within any 
screening programme a number of different strategies exist. Thirdly, formal screening 
programmes require substantial investment in infrastructure. Economic evaluation can 
contribute to decisions whether a new screening programme for a particular disease or 
disorder should be used, and can also aid in decisions about changes to existing 
programmes. 
 
Screening in health care can be viewed as an investment, which yields additional 
information. According to Cairns et al (1993) screening has a number of distinctive 
features: the range of potentially relevant outcomes is broader, the proximate 
investment is in knowledge and not health, patients undergoing screening are 
generally asymptomatic. 
 
Economic evaluation of screening has also a number of distinctive key issues in the 
measurement and valuation of costs and outcomes, sources of data, discounting and 
sensitivity analysis. The economic evaluation of antenatal screening raises additional 
problematic issues. 
 
Economic evaluation studies adopt a broad societal perspective, i.e. the analyst 
considers everyone affected by the intervention and counts all significant health costs 
and outcomes that flow from it, regardless of who experiences the outcomes or costs. 
Implicit in the societal perspective is the recognition that societal resources are limited 
and that health should not be exempted from these limits. (Gold et al 1996). Broad 
perspective means also that the screening is not regarded solely as the test itself 
defining positive or negative result, but as a diagnostic and health care process 
beginning from the screening test (Sintonen 2000).  
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According to Gold et al (1996) health intervention, e.g. screening, imposes changes in 
health care, non-health care and time resources. Health care costs include the 
downstream or negative costs (or savings) associated with the intervention. 
Drummond et al (1997) divides the resource use costs by sectors 1 health care 2 
patient and family 3 other sectors (e.g. other public agencies). He classifies the 
resources saved as part of the consequences, but reports that they mirror the costs and 
are measured and valued in a similar way. In the previous literature costs and benefits 
were often classified as direct, indirect and intangible. Terms direct costs and benefits 
are used to denote the resources consumed (costs) or saved (benefits) by the 
programme. In the main these would be resources in the health care sector. The terms 
indirect costs and benefits are used to denote the time of patients (or their families) 
consumed or freed by programme. Terms intangible costs and benefits are used to 
denote those consequences that are difficult to measure and value (Drummond et al 
1997).     
 
Screening costs are typically partly imposed on the individuals concerned. Costs 
incurred by individuals are likely to have an important effects on behaviour, 
particularly attendance rates (Brown et al 1998). The cost to society of the time taken 
to use health care may differ from the private opportunity cost of such time. Some 
researchers have emphasized that the private opportunity cost of time is a better 
predictor of demand for a screening service than the societal approach (Torgenson et 
al 1994). The valuation principles of the opportunity cost of unpaid inputs are under 
debate among health economists (Posnett et al 1996). Productivity costs are the costs 
associated with a loss or impaired ability to work or engage in leisure activities due to 
morbidity or death. The inclusion of productivity costs is also under debate among 
health economists. According to Gold et al (1996) productivity costs should not be 
included in the cost accounting, as they are included in the denominator of a cost-
utility ratio, e.g. as quality-adjusted life-years saved. This has been  challenged by 
other research groups (Brouwer et al 1997). 
 
The inclusion of health and non-health care costs for unrelated illness in added years 
of life is an unsolved theoretical issue in health economics. Due to the long time-
horizon it is of importance in the economic evaluation of screening. For example, 
would decision makers wish to oppose a smoking prevention program on the basis of 
a cost- effectiveness analysis that included the costs of future health care for 
individuals who were spared from a premature death of lung cancer and other 
smoking-related illness? (Gold et al 1996). For example, Pekurinen (1992) has 
reported that the estimated social costs slightly exceed the social benefits of smoking, 
and that it seems evident, that smoking is profitable to the public sector, apart from 
local authorities. In addition there are practical difficulties in including costs for 
unrelated illness in added years of life. Existing data may not be adequate to capture 
future resource use of all unrelated diseases and it may be unduly difficult to ascertain 
the effect of an intervention on the range of future causes of morbidity and death 
(Gold et al 1996).  
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Typically, economic studies evaluating screening have focused on the outcomes 
associated with true positive findings. The major change in outcomes associated with 
screening will be experienced by this group. For most screening situations, true 
positive results will bring forward the time of detection and allow earlier treatment 
(Brown et al 1998). However, screening unavoidably also medicalizes the screenees 
(Rose 1992). In screening, the test actually places the people into four categories; true 
positive, false positive, true negative and false negative according to whether or not 
they have the disease and whether or not the test result is positive or negative (Thorner 
et al 1961). The monetary values of the different possible results of the different test 
results should also be estimated (Simpson et al 1978). There may also be a small risk 
associated with screening and some pain or discomfort directly associated with the test 
or screen. 
 
A false positive screening result will result in anxiety. Anxiety may be short-lived if 
the results are negative, but may remain for several months, or in some cases years, 
after a false positive result. Anxiety may also be experienced by non-attenders; family 
and friends. All these impacts of false positive screening results have been reported 
e.g. in mammography screening programmes. Negative screening result is usually 
reassuring. False negative screening results may not simply fail to bring forward 
detection, but may provide false reassurance, thereby delaying subsequent clinical 
diagnosis.(Brown et al 1998, Marteau 1990, Stewart-Brown 1997, MacLean et al 
1984, Gram et al 1993).   
 
In screening, information per se may also be valued for its own sake (non-decisional 
value) in addition to its decisional value. Berwick et Weinstein (1985) investigated the 
role of information in a study of willingness-to-pay for ultrasound in normal 
pregnancy.  The average respondent allocated 74 percent of her willingness-to-pay to 
the decisional aspect of the information and 26 percent to information which was not 
used for decision  making. Lange et al (1990) have reported similar results in a cost-
benefit analysis of prenatal screening for autosomal dominant polycystic kidney 
disease.   
  
When assessing the efficacy of an intervention the randomised, double blind 
controlled trial has the highest internal validity, that is, freedom from bias. In practice, 
the blinding is often very difficult to organise in clinical trials. However, as long as 
the data  are drawn from clinical trials, it always lacks knowledge of the real life 
situation, i.e., the clinical trials tend to reach better efficacy than nationwide 
interventions mainly due to more strict clinical protocols and more resources in the 
organisation of the intervention. Effectiveness data from meta-analyses might have the 
advantage that the confidence interval around the point estimate of clinical effect is 
usually narrower than that from an individual trial and the result may be more 
generalisable (Drummond et al 1996). However, in practice possibilities to set up 
large and long-term randomised controlled trials are infrequent, not least because of 
the costs entailed. Where a clinical trial is not feasible, available data can be 
synthesised by modeling techniques. In such circumstances the economic evaluation is 
subject to some uncertainty. Even when economic evaluation has been incorporated in 
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a clinical trial, some modeling is likely to be necessary to allow for differences 
between the trial participants and the target population, to extrapolate from short-term 
outcomes to long-term survival and quality of life. Modeling studies undertaken 
before a clinical trial is initiated can help to identify the key parameters that need to be 
estimated within a planned trial (Brown et al 1998). 
 
Economic analysis takes into account the timing of costs and outcomes. Individuals 
and society prefer resources now rather than later and would prefer to postpone costs. 
This is allowed for in economic evaluation by discounting future costs and outcomes 
to estimate their present value to us now. The rate of discount will vary between 
societies and over time. Consequently it varies between different studies. An 
important issue is, whether the outcomes should be discounted at the same rate as 
costs. Most researchers use the equal rate for costs and outcomes. The most often 
recommended rate is 3% or 5% per annum. However, for example, in Britain the 
Department of Health now recommends that life years and QALYs should be 
discounted at 1.5-2%, and costs at 6 %, respectively. The discount rate for costs and 
outcomes is of great significance for screening, where invariably the costs will occur 
before the outcomes, and where sometimes the outcomes may only arise after several 
decades. The higher the rate of discount applied to outcomes the less attractive 
screening will appear, particularly when compared with those treatment interventions 
that give immediate outcomes (Gold et al 1996, Department of Health 1995, Brown et 
al 1998, van Hout 1998).  
 
In economic analyses uncertainty about estimates of costs, effectiveness, and the C/E 
ratio can arise in a number of ways: Two major sources of uncertainty are 1) 
parameter uncertainty and 2) model uncertainty. Parameter uncertainty is uncertainty 
about the true numerical values of the parameters used as inputs. Model uncertainty 
includes both uncertainty about the correct method for combining these parameters 
and uncertainty introduced by the combination of decisions made by an individual 
analyst (Gold et al 1996).  
 
The standard way of dealing with parameter uncertainty is to use sensitivity analyses. 
Sensitivity analyses should be an essential part of a thorough economic evaluation, 
although at present all studies do not give an adequate account of uncertainty (Briggs 
et al 1995). Sensitivity analyses are mathematical calculations that isolate factors 
involved in an economic analysis to indicate the degree of influence each factor has on 
the outcome of the entire analysis (Gold et al 1996). It measures the uncertainties of 
the analysis. Univariate sensitivity analysis examines one variable, multivariate 
analysis multiple variables, respectively, at a time. In screening, the sensitivity 
analyses are especially important due to the long time horizon and extensive use of 
modeling and discounting. 
 
Also statistical methods can be used, if the source of the uncertainty is the sampling 
variation in estimates of the parameters used in the analysis. Currently, there are three 
ways to provide an estimate of the uncertainty in the estimate of the cost-effectiveness 
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ratio. The first relies on the delta method to calculate the variability of any composite 
measure. The second relies on simulating the variance of the estimated C/E ratio or 
the distribution of the estimated C/E ratio, based on estimates of the variance-
covariance matrix of the parameter estimates. The third is to to derive a bootstrap 
estimate of the probability distribution of the ratio, its confidence interval, or the 
variance in the ratio (Gold et al 1996). 
 
Model structure uncertainty is difficult to incorporate formally. If the magnitude of the 
error that might be introduced by structural assumptions is significant, the qualitative 
remedy appears to be sensitivity analysis, computing the C/E ratio estimate under the 
alternative assumptions and reporting the magnitude of the effect. For quantative 
analysis, a weighed average of the resulting estimates might be computed, with 
weights reflecting the degree of confidence in each structural form (Gold et el 1996).  
 
The economic evaluation of antenatal screening is generally more complex than 
evaluation of programmes, which screen individuals for conditions which might only 
affect those individuals. Antenatal screening raises the issue of saved resources, or 
averted costs, associated with the termination of affected pregnancies. Had the 
affected pregnancy not been detected through screening and terminated, costs would 
have been incurred throughout the affected child’s lifetime to treat the condition for 
which it was screened. These are costs over and above the cost of a ‘replacement’ 
child without the condition. If a health service perspective is adopted, the excess costs 
avoided can be considered equivalent to the health service costs of treating the 
condition which would otherwise have been detected clinically at a later stage.  
 
When the resource use implications for other sectors of society are considered the 
issue comes more complicated: for example, the avoided excess costs associated with 
educational and institutional care, would need to be considered, as well as the costs of 
voluntary services and care incurred by the family. (Cairns et al 1993, Brown et al 
1998).    
 
Some researchers have also tried to quantify the intangible psychological costs to the 
parents from having a handicapped child compared with ‘the greater joy’ they might 
experience from having a ‘replacement’ non-handicapped child, the opportunity for 
the latter arising from the existence of the screening programme (Hendersson 1982). 
 
Antenatal screening also raises many ethical questions. In Finland, in 1985, the 
lutherian state church appointed a multi-disciplinary expert panel on ethical issues 
concerning antenatal screening, infertility treatments and genetics. In their report, 
selective abortion was the main ethical issue of antenatal screening. Selective abortion 
can be defined as an induced abortion of a handicapped fetus. From the christian 
perspective the values of life should not uniquely be effectiveness, success, ease and 
vitality, but the limited capabilities of a human being also have an important meaning. 
All medical diagnostics and treatments should be based on the rights of voluntariness 
and self-determination. According to the panel, in principle three kinds of arguments 
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can be stated for the selective abortion: 1) The life of the child would include 
unreasonable suffering. 2) The life of the parents would include unreasonable 
suffering. 3) The economical and population-political reasons justify selective 
abortions. In their report, the panel concluded, that only the suffering of parents 
should justify selective abortion (Kirkon yhteiskunnallisen työn keskus 1987).       
 
Economic evaluations of screening programmes are population- and health care 
system specific. The disease and participation rates are variable among different 
populations, having a strong effect on the outcome of  an economic evaluation. The 
participation rate is often dependent on the health care system thorough financial and 
organizational features, i.e., the possible fee of the screening, methods of invitation 
and further communication. The quality of the screening cascade differs also in 
different health care systems. Some researchers have proposed methods for carrying 
out  country-specific economic evaluation from multinational or second country-
specific data (Willke et al 1998, van Ineveld et al 1993). 
 
Decision indices are developed for decision making to evaluate choices about health 
interventions. In cost-effectiveness-analysis, cost-effectiveness ratios are computed 
from the societal perspective and placed in rank order. A decision maker can select the 
intervention with the lowest cost per quality-adjusted life-year and continue down the 
list selecting interventions, until the available funds are exhausted. In cost-benefit 
analysis benefit- cost ratios are calculated, and an alternative with a higher benefit-
cost ratio is preferred. The second common option is to select an alternative with a 
higher net benefit or net present value. However, decisions in the real world are more 
complicated. Decision indices provide valuable information about tradeoffs in the 
broad allocation of health resources, but other factors need to be considered as well – 
concepts of fairness and justice and practical questions of feasibility, that are not fully 
captured in the decision indices (Gold et al 1996, Sintonen et al 1997).     
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III REVIEW OF THE LITERATURE 
 
3.1 Economic evaluation of screening programmes in 
Finland 
 
Economic evaluation of the Finnish screening programmes is scarce. Of the ongoing 
Finnish screening programmes breast cancer (Hristova et al 1996) and cervical cancer 
screening have been preliminarily evaluated (Hristova et al 1996). No evaluation has 
been conducted for ultrasound screening during pregnancy in Finland. 
 
Of the potential Finnish screening programmes first-void urine chlamydia trachomatis 
(Paavonen et al 1998) and toxoplasmosis during pregnancy screening (Lappalainen et 
al 1995) programmes have been evaluated. In addition the colorectal cancer screening 
programme has been preliminarily evaluated (Hristova et al 1996). An economic 
evaluation of the possible prostata cancer screening programme is being conducted at 
the moment by National Research and Development Centre for Welfare and Health. 
No evaluation has been conducted from the possible Helicobacter pylori screening 
programme in Finland. 
3.2 Economic evaluation of ultrasound screening in 
pregnancy 
 
The earliest economic evaluations of ultrasound screening in pregnancy reported only 
the rough unit cost of the screening ultrasound examination in pregnancy. None of the 
studies mentioned the principles underlying their estimates nor any detailed cost-
accounting.  Ewigman et al (1993), Persson et al (1983) and Temmermann et al 
(1991) reported the unit cost being $23 to $182 at 1990 prices. Bakketeig et al (1984) 
estimated the cost of screening at $540/pregnancy at 1990 prices. This included two 
ultrasound screening examinations per woman, the increased use of hospital 
resources, loss of time and income for the attending women, and travel. The use of 
antenatal health services varies from more to less use of services in different studies 
(Persson et al 1983, Jörgensen 1992 and Backe et al 1990). 
 
Two cost-effectiveness analyses have reported the cost per identified malformed fetus. 
DeVore (1994) reported the cost for identified malformed fetus as $29 533 or $115 
575 depending on the diagnostic rate of the performers of the ultrasound screening (in 
tertiary centers vs, non-tertiary centers). The effectiveness data were based on the 
RADIUS- study, (RADIUS = Routine Antenatal Diagnostic Imaging With Ultrasound 
Study, 1987-1991 in USA, total number of diagnostic procedures performed 7281) 
which has been criticised of a low detection rate of malformed fetuses (Ewigman et al 
1993). There was a significant difference in the number of malformed fetuses between 
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the tertiary and non-tertiary centers (6.8 vs. 1.7 per 1000, p = 0.001). The cost 
included the estimated health care cost of routine ultrasound examination, based on 
expert opinion. Non-health care or time costs were not included in the analysis.  
 
Roberts et al (1998) reported the cost per target anomaly detected of one second 
trimester ultrasound being in the range  5000 pound sterling to 109 000 pound 
sterling. The objective of the study was to compare the cost-effectiveness of different 
programmes of routine antenatal ultrasound screening to detect four key fetal 
anomalies. The cheapest, but not the most effective, screening programme consisted 
of one second trimester ultrasound. The effectiveness and cost data were derived from 
expert opinion from the Royal College of Obstetricians and Gynaecologists, Working 
Party and secondary data from the literature. The authors concluded that the 
estimation model highlighted the weakness of available evidence and demonstrated 
the need for more information both about current practice and costs. 
 
Waitzman et al (1998) have performed a preliminary benefit-to-cost analysis on a 
policy of routine ultrasound screening for fetal anomalies in the United States. The 
benefit to cost ratio ranged from 0.33 to 3. The cost and benefit estimation was based 
on the RADIUS study and European studies. The analysis focused on the cost savings 
associated with reducing congenital anomalies by terminating pregnancies. The direct 
costs of medical care, special education and development services were included, as 
were the indirect costs of reduction on future returns or productivity due to heightened 
morbidity or premature mortality. Vintzileos et al (2000) only used the RADIUS study 
data and reported the benefit to cost ratio to be between 1.35 and 1.70 in tertiary 
centers and between 0.40 and 0.74 in non-tertiary centers.  
 
3.3 Economic evaluation of breast cancer screening   
 
Breast cancer screening has been economically evaluated by several researchers. 
Brown et al (1999) have concluded in their review of the economic evaluation 
literature of breast cancer screening that a wide range of cost estimates exists across 
studies and that a lack of standardization exists across studies with regard to basic 
economic principles.  
 
Cost-effectiveness analysis has been generally used, using the cost per life year saved 
(LYS) or the cost per quality-adjusted life year saved (QALY) as the main outcome 
measure in the analyses. However, studies of the cost-effectiveness of breast 
carcinoma screening have reported widely differing results, Table 1.  
 
The early C/E studies which reported breast cancer screening to be cost-saving 
assumed very large differentials to exist between the lifetime treatment costs for late -
and early-stage breast cancer, which the later studies have not confirmed (Moskowitz 
1987,Holtzman 1990, Zavertnik et al 1992, Johnson 1988, Brown et al 1993). 
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The trial-based cost-effectiveness studies that exist have seldom been conducted from 
the societal perspective. i.e., the non-health care and time costs have been excluded. 
(U.S. Congress, Office of Technology Assessment 1987, Eddy 1989, Brown 1992, 
Okubo et al 1991, Kattlove et al 1995, Hall et al 1992, Lindfors et al 1995, van 
Ineveld et al 1993, Hristova et al 1996 ).The study of Tabar et al (1989) does not 
report the cost accounting methods at all. 
 
 
The estimated life-years saved and the base cost of screening are the essential basic 
elements of the cost-effectiveness analyses. The variation in the base cost of screening 
ranges from US$18 to US$86 in previously published studies (Table 1), reflecting the 
different cost structures in different countries, but also the different cost accounting 
methods. 
 
Table 1-Previously published C/E ratios 
 
country at prices cost/
(year) LYS 
 (US$)
Gerard et al Australia 89 14 800
Australian Health Ministry Australia 89 7 897
Clarke et al Scotland 89 69 817
Forrest Great Britain 84 4 810
US Office of Technology USA 87 34 600
Eddy USA 84 83 830
Eddy USA 84 21 717
Brown USA 90 30 000
Forsyth USA 1) 37 500
Okubo et al Japan 1) 14 300
van der Maas et al Netherlands 88 4 850
de Koning et al Netherlands 90 3 825
Tabar et al Sweden 1) 3 400
Kattlove et al USA 93 8 280
Hall et al Australia 89 5 321
Lindfors et al general 1) 17 900
van Ineveld et al UK 90 2 844
van Ineveld et al Netherlands 90 3 350
van Ineveld et al France 90 9 164
van Ineveld et al Spain 90 15 326
Norum Norway            1) 21 403
Hristova et al Nordic countr. 1) 15 414
1) data not available
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The estimation of life-years saved is also variable in previously published studies. 
Most authors have assumed the breast cancer mortality reduction to be over 28% 
(Forrest 1987, U.S. Congress, Office of Technology Assessment 1987, van der Maas 
et al 1989, de Koning et al 1991, Lindfors et al 1995, van Ineveld et al 1993, Hristova 
et al 1996, Norum 1999) based mainly on the trial results from the Health Insurance 
Plan of Greater New York and the Swedish Trials (Shapiro et al 1988, Nyström et al 
1993). The majority of published trials and meta-analyses have shown screening 
mammography to reduce breast cancer mortality in women above the age of 50 years 
(Shapiro et al 1988, Tabar et al 1985, Nyström et al 1993, Verbeek et al 1984, 
Kerlikowske et al 1995, Frisell et al 1997, Wald et al 1993). Interestingly, the 
Canadian, Edinburgh and Finnish trials report either no effect or a statistically 
insignificant effect (Miller et al 1992, Kerlikowske et al 1995, Hakama et al 1997, 
Roberts et al 1990, Alexander 1997). Meta-analysis by Gotzsche et al (2000) reported 
mammography screening not to reduce breast cancer mortality. The LYS depend 
crucially on  whether early or late deaths are prevented and in this aspect most 
published trials have relatively short follow-up times.  
 
Eddy (1989) and Okubo et al (1991) have estimated the number of life-years saved 
from an exceptional perspective. Eddy (1989) reported the marginal cost of LYS when 
mammography screening was added to physical breast examination. Okubo et al 
(1991) reported the cost-effectiveness of breast carcinoma screening for the age group 
30-80 years for a period of 50 years,  which  was very different from any other 
screening programme or trial.  
 
There is a broad agreement that in cost-effectiveness analyses all future costs and 
health consequences should be stated in terms of their current value, i.e., discounted. 
Interestingly, Gerard et al (1990),  Forsyth (1988), Okubo et al (1991), Kattlove et al 
(1995), and Hristova et al (1996) did not discount the LYS. 
  
No studies of the cost-effectiveness of nationwide population-based breast carcinoma 
screening have been published. It is noteworthy, that the clinical outcomes of the 
effectiveness that can be achieved are generally from small-scale trials involving a 
limited number of experts, persons examined, and areas. On a national scale, with 
hundreds of professional practitioners, it can be expected to be more difficult to attain 
uniform quality (de Koning 2000).  
 
3.4 Economic evaluation of double-reading mammograms 
 
The double-reading mammograms is a widely used criterion standard in breast cancer 
screening despite a lack of evidence of the cost-effectiveness of the second reading.  
The double-reading practice is reported to be more effective than single-reading 
practice (Anttinen et al 1993, Anderson et al 1994, Brown et al 1996, Ciatto et al 
1995, Warren et al 1995, Blanks et al 1998). The method of double-reading has 
increased the number of breast cancers detected from 5% to 14 % in these studies. 
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Ciatto et al (1995) reported that double-reading detected cancers at an earlier stage 
than single-reading. This result did not reach statistical significance. 
 
Ciatto et al (1995) reported double-reading to cause a marked increase in cost for each 
woman screened (8.5%) and a more limited increase in the cost for each cancer 
detected (3.5%) at the first screening. The costs included only direct health care costs 
of the base screening and the assessment procedures. The reporting of cost-accounting 
principles was limited in this study. Cost – effectiveness was not estimated. 
 
Only one publication on this topic takes comprehensively into account both effects 
and costs (Brown et al 1996). It reports consensus double-reading to be more effective 
and less costly in Britain than a single reading policy. The effectiveness data of this 
study were from an observational, non-randomised trial of 34 000 attenders. A sample 
of 132 attenders provided data for private costs. Costs were estimated from a societal 
perspective. Brown et al (1996) compared three reporting policies: single reading, 
consensus double-reading, and non-consensus double-reading. Consensus double-
reading costs less than single reading (saving £4853 per 10 000 women screened). 
Non-consensus double-reading costs more than a single reading (difference £19 259 
per 10 000 women screened).  
3.5 Economic evaluation of Helicobacter pylori screening 
 
The previous published studies have estimated the financial implications of screening 
for H pylori in one subpopulation, the dyspeptic patients or  from the viewpoint of one 
H pylori related disease, gastric cancer.   
 
Briggs et al (1996) have estimated the cost-effectiveness of identifying patients with H 
pylori and peptic ulcer and of providing eradication treatment compared with 
conventional empirical H sub 2-antagonists treatment.  They  report the screening 
strategy to result in savings after eight years from the screening. Only health care costs 
were included in the Markov model. 
 
Fendrick et al (1999) and Parsonnet et al (1996) reported, that screening and treatment 
for H pylori is potentially cost-effective in the prevention of gastric cancer. These 
analyses do not take into account the benefits of prevention of other H pylori-related 
diseases.  Cost-effectiveness were 6264 US$, at 1996 prices (Fendrick et al 1999) and 
25 000 US$, at 1992 prices (Parsonnet et al 1996) per life year saved in the base case 
analyses. The screening was conducted at age 40 (Fendrick et al 1999) and 50 
(Parsonnet et al 1996) years, prevalence of H pylori infection was estimated as 40% , 
relative risk of cancer in persons with H pylori infection as 3.6. H pylori was 
estimated to prevent 100% (Parsonnet et al 1996) and 30% (Fendrick et al 1999) of 
distal cancers. Distal cancers were assumed to comprise 50-80% (Fendrick et al 1999) 
and 60% (Parsonnet et al 1996) of all gastric cancers. Only health care costs were 
included in these Markov models. Fendrick et al (1999) did not include treatment 
costs for gastric cancer or medical costs for unrelated illness in added life-years  in  
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their baseline analysis. Parsonnet et al (1996) did not include screening office visit 
cost, but did include medical costs for unrelated illness in added life-years. 
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IV AIMS OF THE STUDY 
 
The purpose of the present study was to conduct an economic evaluation of two 
nationwide Finnish screening programmes, and  one pilot Finnish screening 
programme aimed at nationwide use. The reason for choosing these programmes for 
analysis was, that data had become available for conducting economic evaluation.  
 
The specific aims of this study were: 
1 To evaluate the cost-effectiveness of one-stage second trimester ultrasound 
screening in pregnancy in Finland. 
2 To evaluate the cost-effectiveness of nationwide breast carcinoma screening in 
Finland, 1987-1992 
3 To evaluate the cost-effectiveness of double-reading mammograms in Finland.  
4 To carry out a cost-benefit analysis of Helicobacter pylori screening in Finland. 
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V MATERIAL AND METHODS 
 
5.1 Effectiveness data ( I, II,III) 
 
The economic analysis of the one-stage ultrasound screening in pregnancy (I), 
mammography screening (II) and double-reading mammograms (III) was carried out 
as a cost-effectiveness analysis. 
 
The ultrasound effectiveness data (I) came from population-based clinical Helsinki 
Ultrasound Trial (Saari-Kemppainen et al 1990, 1994, 1995), which took place from 
1986 to 1988, and incorporated 9310 women; 95% of all pregnant women in the 
Helsinki metropolitan area. They were randomly allocated to a screening group or a 
control group. Only four women dropped out during the follow-up. 
 
Ultrasound examinations for the screening group took place between the 16th and 20th 
gestational weeks at the Helsinki City Hospital and the University Hospital, and were 
performed by ultrasound-trained nurses. Repeat ultrasound was necessary for 6.5% of 
the women, some of whom also needed further examinations and procedures 
performed by obstetricians. The data on ultrasound findings were collected on pre-
structured forms. At the University Hospital, more time than normal was allocated to 
the study screening examinations. Apart from the study ultrasound examination, the 
screening group and control groups received the same antenatal care, which may have 
included ultrasonography for other than screening purposes at the mother’s own 
doctor’s discretion.  
 
The effectiveness of the ultrasound screening was measured in terms of perinatal 
mortality in the screening group compared to the control group. Data on perinatal 
mortality were collected from hospital records and health-center records of postnatal 
health-center visits. 
 
The effectiveness of mammography screening (II) was measured by life-years saved 
(LYS) due to screening. Finland has had a nationwide population-based breast cancer 
screening programme since 1987, which covers women from 50-59 and can be 
continued up to age 64. The women are screened every second year. The programme 
started gradually with cohorts born in even years, with those born in odd years serving 
as controls, during the first few years of operation.  
 
In the study to the end of 1992 the annual original data (Hakama et al 1997) were used 
for cumulative breast cancer mortality (excluding those cancers diagnosed before the 
screening) in the screening and control groups in the national programme.  The 
number of invitees was 89,893, number of participants 76,389 and number of controls  
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68,862.  The screenees were invited to join the program in 1987-89. They were born 
in 1927-1939 and screened by the Finnish Cancer Society. The controls were the 
women, who were not invited to the screening, matched by age and municipality of 
residence. The follow-up was extended to the end of 1992. Breast cancer cases 
diagnosed at screening, interval cancers, cancers diagnosed among the women invited 
but not screened, cancers diagnosed in the control cohorts, and deaths from breast 
cancer was identified by linkage to the Finnish Cancer Registry (Hakama et al 1997). 
 
From the beginning of 1993 an estimation model was used, i.e., the total LYS were 
estimated by adding the LYS in 1987-1992 to the LYS estimated by the model from 
1993 onwards. The LYS were estimated to the year 2020, i.e., when the discounted 
annual LYS would be under 5 years, and the average age of the screening group 87 
years.  
 
Of the breast cancer cases diagnosed from 1987 to 1992, assuming no screening, the 
number succumbing annually between 1993 and 2020 was estimated based on the age-
specific 1980-84 national cumulative breast cancer survival rates (Finnish Cancer 
Registry) for the 12 years following diagnosis. After 12 years, national mortality rates 
at age of the patients were applied to the patient population with more than 12 years of 
survival. The survival rates were multiplied by 0.985, indicating persistent excess 
relative mortality due to breast cancer among the patients. In addition, the cumulative 
relative mortality was corrected by a constant multiple of 0.8 due to an assumed 20% 
improvement in breast cancer survival from 1993 to 2020 compared to the period 
1980 to 1984.   
 
The LYS were estimated under three optional models. In the base case model 
screening was assumed to lower cumulative relative (i.e. breast cancer) mortality by 
0% in the first year after diagnosis, by 12% in the second year and by 24% in the third 
and fourth years. In the fifth year, the cumulative relative mortality reduction, was 
assumed to equal the reduction of the fourth year plus 12% of the marginal, ( i.e. 
additional) relative,  mortality. After the fifth year, cumulative relative mortality 
reduction was assumed to remain constant, i.e., annual mortality in the screening and 
the no-screening groups was assumed to remain the same. After the fifth year the 
cumulative relative mortality reduction was not assumed to increase. (Shapiro et al 
1988, Nyström et al 1993, Hakama et al 1997).   
 
In the second case model, the screening effect was estimated to equal that of the first 
model during the first four years after diagnosis. In the fifth year, the cumulative 
relative mortality reduction was assumed to be the reduction of the fourth year plus 
18% of the marginal relative mortality. In the sixth year, cumulative relative mortality 
reduction was assumed to be the reduction of the fifth year plus 12% of the marginal 
relative mortality. In the seventh year, the cumulative relative mortality reduction was 
assumed to be the reduction of the sixth year plus  6% of marginal relative mortality. 
After the seventh year, annual mortality in the screening and the no-screening groups 
was assumed to remain the same.  
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In the third case model, annual mortality was assumed to remain the same in the 
screening and no-screening groups after the end of the screening in 1992.  
 
In all three models the all-cause life-years saved were obtained by annually 
multiplying cumulative relative breast cancer-mortality reduction by the age-specific 
population mortality.  
 
The double-reading effectiveness material (II) consists of  95 423 mammographs 
performed during 1990-1995 in three screening centers (Pori, Jyväskylä, and Kuopio) 
of the Finnish Cancer Society , representing about 15% of the total screening activity 
in Finland during that period. The participation rate was 91%. 
 
The material is retrospective, measuring the effectiveness of the actually used double 
reading strategy All mammograms are read by two radiologists, chronologically the 
first and second reader. However, in practice, the second reader had access to the 
reading result of the first, i.e., the double reading was not all blind. In addition to the 
double reading, some centres have had consensus reading for some of the 
mammograms. Consensus reading was performed by one senior radiologist or by a 
group of two to four radiologists. 
 
The centres recorded the readings of the first and the second reader on a grading scale 
of: 1 normal, 2 benign, 3 mild malignant suspected, 4 strong malignant suspected, 5 
malignant. Grades 3-5 mean that the reader considers further assessment useful. The 
number of further assessment procedures, the number of surgeries and the diagnosis 
are also recorded. 
 
We compared two strategies for reporting within a screening program: 
1) Single-reading strategy with possible consensus reading, i.e., assuming only one 
reader performed the original reading. 
2) Double-reading strategy with possible consensus reading, i.e., the strategy actually 
used. 
The main indicator of effectiveness was the actual number of cancers detected, based 
on their histological diagnosis. This number of cancers detected by single-reading 
strategy was estimated assuming that all the cancers originally graded 3-5 by the first 
reader would have been detected by the single reading, but none of graded 1-2 by the 
first reader would have been thus detected. The effectiveness of the double reading 
was the difference between number of cancers detected in the double -reading strategy 
and that for the single reading. The chi-square test served to compare incremental 
effectiveness of  different screening centers statistically. Due to the incomplete data on 
interval cancers within the Finnish national screening program,  the definition of 
effectiveness did not include the potential where the initial reader read 3-5 and the 
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second reader 1-2 with subsequent consensus of 1-2 suggesting the first reader was an 
possible “over” read.  
 
Differences between double and single reading strategies were further assessed by the 
mean size of lesions in mammography, the mean size of lesions in microscopy and 
stage distribution. Data for these comparisons came from two screening centers 
(Kuopio and Jyväskylä). Student’s t-test and the chi-square test served in analysis of 
statistical differences. 
 
5.2 Cost data (I, II, III) 
 
Costs were evaluated from the societal perspective, i.e.,  including health-care, non-
health care and time costs. The ultrasound study (I) was conducted a couple of years 
before the breast cancer(I) and double reading mammograms studies (III). The 
generally used cost terminology was in a change during that time, which led to 
variability in the use of cost terms among the studies. In the ultrasound screening 
study terms direct and indirect costs are used. Direct costs were costs which were 
directly caused by the health program. Indirect costs were lost working time costs and 
travel costs. Positive costs were actual realised costs, and negative costs represented 
savings due to lower use of health services. When representing the results, the 
following terms were used: gross cost = only the positive costs included, net cost 1 to 
3, the positive costs included, but negative costs, i.e. savings to different degrees 
included. In the mammography screening study (II) and double reading mammograms 
study (III) the costs were divided according to Gold et al (1996) into health care, non-
health care and time costs. Health care costs included also the health care savings 
caused by the screening programme. Non-health care costs were travel costs.   
 
In the ultrasound screening in pregnancy (I) the main cost-causing events were the 
base cost of screening, the ultrasound-induced advanced examinations,and the 
savings, i.e., negative costs due to fewer inpatient and outpatient visits and fewer other 
ultrasounds. Later we also obtained data of the additional use of other health services, 
which represent part of the total cost. These data were collected from every woman 
participating in the trial. The differences between the comparison groups were 
evaluated by Student’s t-test. 
 
Cost-accounting data were collected via a questionnaire for all attenders, and were 
later completed by a postal questionnaire to 534 of the screened women. The sample 
was a stratified random sample to equal sample size by health center. The response 
rate was 76%. The responding and non-responding groups were fairly similar, 
measured by income, age and distance to health center. Further cost accounting 
sources were internal accounting and health-market data and statistics. 
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In the mammography screening (II) and double-reading mammograms (III) the main 
cost-causing events were:1 base costs of screening, 2 costs of recall assessment, 3 
surgery costs for false positives, 4 savings due to early treatment of breast cancer. In 
the mammography screening study we also estimated the costs of treatment caused by 
over-diagnosis. In double-reading costs we included all the relevant incremental costs 
associated with the double-reading strategy compared to the single-reading. 
  
The first mammography represented the base health care cost of screening. In Finland 
a two-view projection is used. The costs were derived from the 1995 internal accounts 
from the four main screening organizations in Finland. Adjustments were made to 
standardize the different accounting methods. The mean national base health care cost 
of screening and assessment was calculated by weighting the results with the market 
shares of the organizations.  
 
The base non-health care cost of screening was for transportation. The time cost was 
the opportunity cost of time actually spent on the mammography, as well as the 
transportation and waiting times. The cost data were collected by questionnaire from 
1400 attendees at the screening examination, a stratified random sample to equal 
sample size by the national statistical grouping into residents by municipalities 
(Statistics Finland 1995). The questionnaire was distributed in 10 randomly selected 
screening units in Finland from April 1996 to June 1996. We received 1294 returned 
questionnaires (92%). All the cost estimates were aggregated from individual data. 
When any piece of information was missing, it was replaced by the sample average. 
The opportunity cost of time was regarded as zero for women who didn’t use working 
time for the examination. For those women, who were employed at the time of 
examination and who used working time for the examination, the opportunity cost of 
time was the time spent multiplied by the hourly wage rate (including employer’s 
social expenses; national average 40.7% of the salary).  
 
The health care cost of recall assessment consisted of the repeated or detailed 
mammograms, ultrasound and ultrasound + fine needle biopsy costs.  The proportion 
of women further examined and the proportion of fine needle biopsies came from a 
Finnish study (Pamilo et al 1995), showing the equivalent national figures from all 
screening units in Finland during this period. The proportion of repeated 
mammographs and ultrasounds of women further examined in total was assumed to be 
the same as during 1990-95 in Kuopio and Jyväskylä, two screening units of the 
Cancer Society of Finland.  Under these assumptions, 3.5% of the screened women 
were recalled for further assessment,  2.7% were remammographed,  2.3% underwent 
ultrasound,  0.9% fine-needle biopsy and 0.7% surgery. The non- health care cost of 
transportation and the time cost were assumed to be 1.5 times higher than for the base 
screening due to the longer distances to the assessment locations.  
 
In the double-reading study (II) the number of incremental further assessment 
procedures were recorded in each screening centres.  The mean national cost served as 
basis for the cost estimate. 
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The health care costs for surgery on the false positives were from two major hospitals 
for breast cancer surgery in Finland: Helsinki City Hospital and Kuopio University 
Hospital. The transportation cost for the surgery for positives was assumed to be twice 
as high as in the mammography screening. Evaluation of time cost was based on the 
results of the cost survey of the screening attendees and the data on average sick leave 
caused by the operation. It was assumed that all employed women used working time 
for the procedure and the following sick leave. The surgery cost of the true positives is 
included in the saving due to early treatment. 
 
The saving due to early treatment was based on data on the difference in stage 
distribution with and without screening. The data on the national stage distribution 
from 1980-84 and 1990-94 came from the Finnish Cancer Registry, and were defined 
as localized or non-localized. The period 1980-84 represented the no-screening 
situation and 1990-94 the screening situation. The treatment cost for the localized and 
non-localized cancers came from a Finnish study (Parvinen et al 1996), of costs of  all 
breast cancers in the area of Turku in 1981 (30 non-localized and 20 localized breast 
cancers) , for which health-resource use  was followed up for nine years or the 
patient’s death.  Outpatient visits and inpatient days for localized and non-localized 
cancer are based on a study of 535 patients diagnosed in 1977-80 in the Tampere area 
and followed up for five years after diagnosis or until death (Holli et al 1996).  
Transportation time was estimated as twice as high as in the base mammography 
screening, since the treatment mainly took place in the five University Hospitals. The 
time cost was calculated assuming that all the employed women used working time 
for the treatment.  
 
Cost of treatment caused by over-diagnosis is due to the possible over-diagnosis of 
carcinoma in situ in the cancers detected by screening. The natural history of 
carcinoma in situ is unknown, but it seems to be a high-risk marker rather than an 
invariable precursor of invasive disease (Wright et al 1995, Ernster et al 1996, Page et 
al 1982, Rosen et al 1982). In the age group 50-59 the national number of new breast 
carcinoma in situ (ductal and non-ductal) and new breast carcinoma in total were 
obtained from the Finnish Cancer Registry for the period 1980-84 and 1990-94. The 
1990-94 proportions were applied to the screening group. The cost of treating 72% 
(Page et al 1982) of those new  intraductal breast cancers and 62% (Rosen et al 1978) 
of those new non-ductal breast cancers in situ which exceeded the proportion of 
equivalent carcinomas in situ to carcinomas in total estimated from the 1980-84 data, 
was assumed to be the cost of over-treatment cost of breast carcinoma due to 
screening.  
 
5.3 Measure of cost-effectiveness (I, II, III) 
 
The cost-effectiveness of ultrasound screening in pregnancy (I) was estimated by 
dividing cost difference by the difference in perinatal deaths between the screening 
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and control groups. The main outcome measure was the cost of avoiding one perinatal 
death. 
 
The cost-effectiveness of mammography screening (II) was estimated by dividing the 
costs of screening in the period 1987-92 by the total estimated number of life-years 
saved in the period 1987-2020 according to the three sets of assumptions described in 
models 1 to 3. 
  
The main outcome measure of the cost-effectiveness of double-reading mammograms 
(III) was the incremental cost per additional cancer found due to the practice of double 
reading. 
 
5.4 Costs and benefits in cost-benefit analysis (IV) 
 
 
The economic evaluation of Helicobacter pylori screening was carried out as a cost-
benefit analysis using a computer-based decision tree (SMLTree). A full cost-benefit 
analysis measures all costs and consequences in dollars. However, in practice cost-
benefit analyses often amount to a comparison of those costs and benefits, that can be 
easily expressed in money terms (Drummond et al 1997). Also in our cost- benefit 
analysis the scope was restricted. Only health care costs were included in the analysis, 
i.e. non- health care costs and time costs were not included. Health care costs did also 
include the possible health care savings, which thus represented the benefit of the 
screening. We did not put monetary value on changes in health state, e.g. death due to 
gastric cancer. Thus, some researchers would classify the present analysis as cost 
analysis, not cost-benefit analysis.   
 
A decision tree is composed of three types of nodes. Decision node branches 
correspond to strategies that the decision maker has control over, i.e. to screen or not 
to screen. Chance node branches correspond to events over which the  decision maker 
has no  control, but can predict with certain probabilities, e.g., the lifetime probability 
of developing gastric cancer. Terminal nodes correspond to final outcome states. They 
contain utility expressions, i.e. monetary values, which describe the value of the state. 
When a chance node is evaluated, the probability of each branch is multiplied by the 
value of the node at the end of the branch and all such products are summed up to 
form an expectation (Hollenberg 1993). 
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The primary decision analysis compared two intervention strategies. 1) screen for H 
pylori and treat those individuals with a positive test, and 2) do not screen for H pylori 
and test and treat H pylori only if  related clinical symptoms appear. The model 
estimated the discounted H pylori-related accumulated health care costs from 
screening age to death in both strategies.  The age at screening was 15-45 years in the 
base case and 15, 30 and 45 years in the sensitivity analyses.  
 
The main outcome measure is the incremental health care cost per case, i.e., person 
invited for screening, in the screening alternative compared to no-screening 
alternative. In addition, the incremental cost per treated H pylori infection due to 
screening is presented.  
 
The participation, visit and compliance rates, prevalence of H pylori antibodies, 
effectiveness of H pylori treatment (i.e. eradication rate), and sensitivity and 
specificity of the H pylori serological screening test were obtained from the Vammala 
H pylori screen and treat project (Salomaa et al 1998). The population-based screen 
and treat project started in 1996 in Vammala, a semi-urban community in southwest 
Finland. In 1996, all subjects aged 15 to 40 years, and in 1997 and 1998, all subjects 
aged 15 and 45 years, living in Vammala, were invited by mail to participate in the 
project. Serum IgG and IgA antibodies to H pylori were determined by enzyme 
immunoassay, the lower limits of raised titres were 700 for IgG and 70 for IgA 
antibodies. Within these limits, the sensitivity and specificity of the tests were 94% 
and 93%, respectively (Kosunen et al 1997). The minimum and maximum values for 
sensitivity analyses were obtained from published studies (van Der Ende et al 1999, 
Meijer et al 1997, Xia et al 2000). All antibody-positive subjects were invited to visit 
100
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infected
not infected
infected
not infected
no screen
screen pPREVALENCE
pPREVALENCE
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a GP and offered eradication therapy . The first-line therapy was amoxycillin 1000 mg 
x 2, metronidazole 400 mg x 3 and lanzoprazole 30 mg x 2 for one week. Serological 
follow-up occurred 6 months later. Treatment failures were offered a second 
eradication therapy by phone. Second treatment failures were offered gastroscopy, 
including antibiotic sensitivity testing, which served as a basis for the third individual 
treatment regimen. In 1996-1998, 5288 subjects entered the project. These data were 
used in the current analysis, with the exception that the cost of the one-week therapy 
was replaced with the cost of the currently recommended therapy; i.e., amoxycillin 
1000 mg x 2, clarithromycin 500 mg x 2 and omeprazol 20 mg x 2 for one week.  To 
simplify the model, no third treatment failure was assumed to exist, and the sensitivity 
and specificity of the retests were assumed to equal to 100%. 
 
Participation rate was defined as the number of patients who gave serum samples / the 
number of invited patients. Visit rate was the number of patients who visited the GP / 
the number of patients who had positive screening samples. Compliance rate was the 
number of patients who took the prescribed drugs and gave a follow-up sample 6 
months later / the number of positive patients who visited the GP. The second and 
third compliance rates were the number of patients who took the prescribed drugs and 
gave a follow-up sample 6 months later / the number of patients who had positive 
follow-up samples. 
 
At screening, the prevalence of Hp antibodies, indicating infection was 13%, 
participation rate 76%, visit rate 87% and compliance rate 91% in 15 to 45-year-olds.  
The effectiveness of the first treatment was 81%. Neither re-infection after cure nor 
spontaneous eradication in the absence of therapy were included in the model (Table 
2). 
   
Probability estimates for H pylori – related disease variables were obtained from 
published reports and national statistics (Table 3, Forman 1995, Forman 1994, The 
Table 2. Probability estimates for H pylori screening-related variables in Decision Tree Analysis.
Variable Probabilities
Base Alternative
Case Models
  Age at screening(years) Min. Max.
  15 30 45 Value Value
Participation rate 0,76 0,91 0,74 0,70 0,61 0,90
Prevalence 0,13 0,03 0,13 0,29 0,10 0,16
Screening test (serology) sensitivity 0,97 0,90 0,98
Visit rate 0,87 0,75 0,87 0,79 0,70 0,90
First Compliance rate 1) 0,86 0,78 0,85 0,91 0,69 0,90
Effectiveness of first treatment (one week) 0,81 0,65 0,90
Second compliance rate 2) 0,47
Effectiveness of second treatment 0,82
Third compliance rate 2) 0,50
Screening test specificity 0,93 0,90 0,98
VS = Vammala Helicobacter pylori screen and treat project
* maximum value estimated at 0.90
1) number of patients who took prescribed drugs and gave follow-up sample 6 months later / number of Hp- positive patients who visited GP
2)number of patients who took prescribed drugs and gave follow-up sample 6 months later/ number of patients who had positive follow-up sample
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Eurogast Study Group 1993, Graham 1997, Parsonnet 1998, Kuipers 1999, Kokkola et 
al 1996, Calam 1998, Ihamäki et al 1979, Sipponen et al 1990, Cullen et al 1993, 
Dixon et al 1992, Sipponen 1995, Dew 1987, Varis 1988, Katschinski et al 1994, van 
Der Hulst et al 1997, Elashoff et al 1983, Danesh et al 2000, Miwa et al 2000, 
Moayyedi et al 1999, Greeberg et al 1999, Talley et al 1999, Gilvarry et al 1997, 
McColl et al 1998, Peeters 1998). Helicobacter pylori infection was regarded as a risk 
factor for gastric cancer, gastric premalignant conditions, duodenal ulcer, gastric ulcer 
and in certain analyses for dyspepsia. 
 
 
The observed sex-adjusted gastric cancer incidence rates by  birth cohort were 
obtained from the Finnish Cancer Registry. The gastric cancer statistics include all 
cancers whose primary site is the stomach, e.g., gastric lymphomas, which are also 
strongly associated with H pylori (Wotherspoon et al 1991). The cohort-specific risks 
have decreased quite steadily over time, with the risk between successive cohorts 
appearing to be fairly constant (Hakulinen et al 1986). We assumed that the ratio of 
the risks for successive birth-year cohorts to be fairly constant for the 1968 birth 
cohort (aged 30 years in 1998). The lifetime risk of developing gastric cancer in the 
Table 3. Probability estimates for H pylori-related disease variables in Decision Tree Analysis.
Variable Probabilities
Base Alternative
Case Models
Min. Max.
 
Value Value
Cancer, Lifetime probability of gastric cancer in general population a) 0,004
Cancer, Hp-related gastric cancers of all gastric cancers 0,73
Cancer, Lifetime probability of Hp-related gastric cancer, if Hp+ b) 0,0225 0,005 0,03
PL, Lifetime probability of diagnosed Hp-related PL, if Hp+ 0,0898 0,02 0,12
PL, Probability of operational treatment 0,11
DU, Lifetime probability of DU in general population 0,1
DU, Proportion of DU Hp+ 0,95
DU, Hp prevalence in population, where DU probability studied 0,8
DU, Lifetime probability of Hp-related DU, if Hp+ c) 0,12 0,11 0,22
DU, Diagnosed in emergency care 0,05
DU, Propability of survival, when DU diagnosed in emergency care 0,92
DU, Probability of bleeding complications 0,0042   
GU, Lifetime probability of GU in general population 0,035
GU,  Proportion of GU Hp+ 0,8
GU,  Hp prevalence in population, where GU probability studied 0,8
GU, Lifetime probability of Hp-related GU, if Hp+ d) 0,028 0,02 0,04
GU, Diagnosed in emergency care 0,05
GU, Probability of survival, when GU diagnosed in emergency care 0,92
GU, Probability of bleeding complications 0,0021   
Dyspepsia, Lifetime probability of Hp-related funct. dyspepsia, if Hp+ 0,05 0 0,1
Dyspepsia, Helicotest UBT sensitivity 0,98
Dyspepsia, Compliance 0,91 0,73 0,95
a) Finnish Cancer Registry
b) =  (1/prevalence) x (pcancer  x proport.H pylori +)
c) =0,1x0,95x(1/0,8)
d) =0,035x0,8x0,8x(1/0,8)
PL = Premalignant lesions
Hp = Helicobacter pylori
DU = Duodenal ulcer
GU = Gastric ulcer
VS = Vammala Helicobacter pylori screen and treat project
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general 1968 birth cohort was obtained by  multiplying the estimated age-specific 
gastric cancer incidence rates by the age-specific population mortality (Statistics 
Finland 1999) and then  summing up these figures. The lifetime probability of gastric 
cancer was estimated to be 0.4% in the 30-year-old general population.  We assumed 
that 73% of all gastric cancers are caused by H pylori infection. (Forman 1995, 
Forman 1994, Eurogast Study Group 1993). The lifetime probability of infected 1968 
birth cohort to develop H pylori caused gastric cancer was estimated at 2.25 % 
(1/prevalence) x (probability of cancer in the general 1968 birth cohort) x (proportion 
of cancers caused by H pylori).  In the sensitivity analysis, minimum and maximum 
values of 0.5% and 3.0% were used (Parsonnet 1998, Graham 1997). (Table 3)  
 
The lifetime probability of diagnosed H pylori-related premalignant conditions in 
infected patients was estimated at 8.98%. Kuipers (1999) reported an 8-fold risk of 
developing gastric premalignant lesion as compared with  gastric cancer. However, his 
baseline risk estimate for gastric cancer was only 1%. We conservatively assumed a 4-
fold risk of developing gastric premalignant conditions as compared with gastric 
cancer (Table 3). 
 
The lifetime probabilities of H pylori related duodenal or gastric ulcers in infected 
patients were estimated as follows:  (lifetime probability of duodenal/gastric ulcers in 
general population) x (proportion of  duodenal/gastric ulcers caused by H pylori) x (1/ 
H pylori prevalence in the age cohort for which duodenal/gastric ulcer probability 
used). The estimated lifetime probabilities of H pylori related duodenal and gastric 
ulcers in infected patients were 12% (0.1 x 0.95 x (1/(0.8)) and  2.8% (0.035 x 0.8 x 
(1/(0.8)) in the baseline case (Kokkola et al 1996, Calam 1998, Ihamäki et al 1979, 
Cullen et al 1993, Dixon et al 1992) (Table 3).  The probability of ulcer bleeding after 
H pylori diagnosis and treatment was estimated to be as low as 0.4%, because there is 
strong evidence for the benefits associated with the current clinical practice of 
eradication H pylori in patients with a confirmed ulcer (van der Hulst et al 1997, 
Elashoff et al 1983). 
 
The lifetime probability of H pylori related diagnosed dyspepsia in infected 
individuals is controversial (Danesh et al 2000, Miwa et al 2000, Moayeddi et al 1999, 
Greenberg et al 1999, Talley et al 1999, Gilvarry et al 1999, McColl et al 1998).We 
assumed the lifetime probability of H pylori related diagnosed dyspepsia in infected 
patients in the baseline at 5%. (Table 3). 
 
The life-time probability of Helicobacter pylori-related morbidity, treatments and 
mortality were estimated to be equal for the screening group non-participants and the 
no-screening group.    
 
Only health care costs were included in the model. Unit treatment cost data were 
obtained from Helsinki University Hospital, Uusimaa Health District (Helsinki 
University Central Hospital 1999, Uusimaa Health District 1999) and from in-house 
cost data of Helsinki City Department of Health.  The drug costs were at retail market 
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prices (Lääketietokeskus 1999). Treatment-associated adverse events and their 
treatment were included in the model.   
 
The aggregated health care cost of gastric cancer in the baseline case was estimated as 
US$ 13 413. This included costs before and after diagnosis. The average number of 
different cost events prior to diagnosis was obtained from a published article 
(Suvakovic et al 1997) and complemented by  expert opinion. The source of gastric 
cancer treatment cost after diagnosis was the National Research and Development 
Center for Welfare and Health. All new gastric cancer patients (n= 467) diagnosed in 
1992-93 in the Helsinki University Hospital district were included in the cost analysis. 
Patient-specific numbers of in-patient treatment periods in regional, central, university 
or other hospitals were obtained from the national statistics. In-patient treatment 
periods in the 5 years following cancer diagnosis were included when g astric cancer 
was recorded as one of the main diagnosis for treatment. The average unit costs for in-
patient treatment periods and outpatient visits in different hospital types were obtained 
from hospitals’ in-house cost data. This was also the source for the average number of 
outpatient visits per year for a gastric cancer patient. The average number of patients 
using outpatient services was estimated from the annual relative survival (Dickman et 
al 1999) and all-cause survival rates (Statistics Finland 1999) (Table 4). 
 
The costs of gastric premalignant conditions, duodenal and gastric ulcers and 
dyspepsia were the resource use costs. The relevant cost-causing events were 
estimated partly based on expert opinion and partly on published articles. All H pylori 
infections were estimated to be diagnosed in patients with confirmed gastric 
premalignant lesions, duodenal or gastric ulcers.H pylori serology tests in addition to 
H pylori gastroscopy specimen tests were estimated to have been taken in 8% of cases 
(Laine et al 1997). Compliance with H pylori eradication treatment was assessed to be 
100%, in patients with gastric premalignant lesions, duodenal or gastic ulcers. 
Compliance was estimated to equal the screening ( 91%), if the patient had been 
diagnosed with dyspepsia. The effectiveness of H pylori treatment was estimated to 
equal the effectiveness rate observed at screening.  (Table 4). 
 
The cost-causing events of gastric premalignant lesions included events prior to 
diagnosis, diagnosis, eradication and follow-up. Follow-up consisted of 3 
gastroscopies and specialist visits (Kokkola et al 1996), taking into account the all-
cause mortality. The main cost-causing events of duodenal and gastric ulcers were 
events prior to diagnosis, diagnosis, H pylori eradication treatment and possible 
bleeding complications. The cost-causing events of dyspepsia included events prior to 
diagnosis, immediate or delayed diagnosis and eradication. (Table 4). 
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5.5 Valuation and discounting (I, II, III, IV)  
 
In the ultrasound study all cost data were estimated at the 1990 price level, in the 
breast cancer screening and double-reading mammograms at the 1995 price level and 
in the H pylori study at the 1998/99 price level using indices. FIM values were 
converted to US$ by the official exchange rates, i.e. US$1.00 = FIM 3.85 in 1990, 
US$ 1.00 = FIM 4.37 in 1995 and US$1.00 = FIM 5.54 in 1999. 
In the ultrasound study no discounting was needed , because the time period was the 
length of one pregnancy. In the breast cancer screening, double-reading mammograms 
and H pylori screening studies a discount rate of 3% was used (Gold et al 1996).    
 
For the timing of the cost-causing events the data on attendance and difference in 
breast cancer mortality by calendar year came from the Finnish Cancer Registry. The 
number of screened women was recorded annually for the years 1987-89. The number 
of screened women in 1990-92 is based on the estimate that 90% of the women who 
once have entered the screening program, will continue in the program and will be 
screened every second year until 1992. The national mean participation rate has been 
88.6% in Finland for the years 1987-94 (Pamilo et al 1995). The assessment and 
surgery were assumed to take place in the same calendar year as the screening.  The 
savings were assumed to be equally distributed over the five years following 
Table 4. Selected undiscounted aggregated costs (US$ 1998/99) in Decision Tree
Analysis.
Cost-causing event US$
Screening, participate, infected, test sensitive, visit, compliant, 1st treatment effective 232
Screening, participate, infected, test sensitive, visit, compliant, 2nd treatment effective 308
Screening, participate, infected, test sensitive, visit, compliant, 3rd treatment effective 722
Screening, participate, not infected, test specific 29
Screening, participate, not infected, test specific, visit, compliant 232
Gastric cancer, treatments and examinations prior to diagnosis a) 1227
Gastric cancer, treatment 13434
Premalignant lesion, treatments and examinations prior to the diagnosis a) 713
Premalignant lesion, treatment, surgery 4841
Premalignant lesion, treatment, no surgery 2999
DU, treatments and examinations prior to diagnosis a) 478
DU, emergency diagnosis, survival, later bleeding 7154
DU, emergency diagnosis, survival, no later bleeding 2498
DU, emergency diagnosis, no survival 9340
DU, no emergency diagnosis, later bleeding 5714
DU, no emergency diagnosis, no later bleeding 1058
GU, treatments and examinations prior to diagnosis a) 709
GU, emergency diagnosis, survival, later bleeding 7720
Dyspepsia, treatments and examinations prior to diagnosis a) 209
Dyspepsia, test sensitive, compliant 800
Dyspepsia, test sensitive, not compliant 937
Dyspepsia, test not sensitive, later diagnosis and treatment 989
Hp = Helicobacter pylori
DU = Duodenal ulcer
GU = Gastric ulcer
a) costs prior to diagnosis are included in aggregate costs
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diagnosis, because more specific data were unavailable. Over-treatment costs were 
equally distributed over the two years following the diagnosis, because carcinoma in 
situ is a localised carcinoma, usually treated immediately after diagnosis. 
 
The average age at diagnosis of H pylori caused disease was obtained from published 
articles. The age at diagnosis was 69 years in gastric cancer (Dickman et al 1999), 63 
years in gastric premalignant lesions (Ihamäki et al 1979), 51 years in duodenal ulcers 
and 59 years in gastric ulcers (Kekki et al 1990). The average age of 45 years at 
diagnosis of dyspepsia was based on expert opinion. 
 
5.6 Sensitivity analysis (I, II, III, IV) 
 
In the ultrasound study (I) the costs and cost-effectiveness were calculated under five 
different model variations: 
Table 5. Cost calculation model variations in the ultrasound screening study  
cost type gross 
cost 
Net 
cost 1 
net cost 
2 
net cost 
3 
net cost 
4 
screening 
induced costs 
x X x x x 
savings from other use of antenatal 
outpatient services 
  x  x x x 
savings from other use of antenatal 
inpatient services 
    x x x 
savings from 
other use of other ultrasounds 
   x x 
Costs of other use of antenatal maternal 
health center 
    x 
 
  
 
Univariate sensitivity analysis was applied to proportionally large or uncertain cost 
items, and the changes used were +/- 5% and +/- 10%. 
 
The cost-effectiveness of mammography screening (II) was estimated under different 
model assumptions: I base case, II surgery cost only for clinically evaluated, 
unnecessary false positives (Jahkola et al 1991), III no over-treatment cost, IV time 
cost for all attendees, based on the average salary of the sample, V no transportation 
and time cost, VI discount rate 5%, VII no over-treatment, transportation and time 
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cost, discount rate 5%, VIII difference in breast cancer survival constant after 8 years 
from diagnosis in screening and no-screening groups, IX difference in breast cancer 
survival constant after end of screening (1992) in screening and no-screening groups. 
In the univariate sensitivity analysis the base case model parameters were changed by 
+/-5%. 
 
The incremental cost-effectiveness ratios of double-reading mammograms (III) were 
estimated for each of the three screening centers separately. The ratio was also 
estimated solely for invasive cancers, excluding the carcinoma in situ cases. This 
estimation was based on the sub-sample of two screening centers, assuming that the 
incidence of carcinoma in situ in the third center (Pori) was the weighed average of 
the sub-sample of the two centers (Kuopio and Jyväskylä). In addition we calculated 
the incremental C/E ratio when the base case model parameters were changed by +/- 
10 %, i.e., univariate sensitivity analysis was performed. 
 
In the Helicobacter pylori study univariate sensitivity analyses were performed by 
changing the values of selected key baseline variables.  The screening - related 
baseline probabilities were changed by +/- 20%, notwithstanding the probabilities of 
participation, visit, compliance and effectiveness of treatment rates, which were not 
estimated to exceed 90%. The analysed ranges for screening test sensitivity and 
specificity were 90-98%. The H pylori-related disease probability ranges were 
obtained from published articles (Tables 2,3).  
 
The base cost of screening, i.e., the costs of the screening test and GP visit, was 
changed by +/- 20% in the sensitivity analysis, as well as the aggregated costs of H 
pylori-related diseases. 
 
In multivariate sensitivity analyses, we estimated the cost-benefit of H pylori 
screening when the age at screening was 15, 30 or 45 years. The simultaneously 
adjusted age-specific variables were participation, visit and compliance rates, 
prevalence and all the discounted cost variables. The age-specific screening data were 
obtained from the Finnish Vammala H pylori screen and treat project. Data for 15 to 
17-year-olds were used in the analysis of the group aged 15 years (n=988), data for 28 
to 32-year-olds in the group aged 30 years (n=832) and data for 45-year-olds in the 
group aged 45 years (n= 478).  
 
A multivariate sensitivity analysis was performed, where all lifetime probabilities to 
develop H pylori-related disease (gastric cancer, gastric premalignant lesions, 
duodenal and gastric ulcers, dyspepsia) were simultaneously changed to minimum or 
maximum values. 
 
A probabilistic sensitivity analysis was performed with a Monte Carlo simulation of 
1000 cases. For the simulation, a logistic or uniform probability distribution was 
created for the ranges of the selected 22 key variables. In each case, a parameter value 
 42
was randomly selected from the distribution functions. For other variables, baseline 
values were used. Thus, the expected cost was calculated with the decision tree for 
each case, and based on these costs, the mean and standard deviation (SD) was 
derived for both alternatives (Doubilet et al 1985). 
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6 RESULTS 
 
6.1 Ultrasound screening in pregnancy (I) 
 
The main effect of ultrasound screening was significantly lower perinatal mortality in 
the screened compared with the control group. Nineteen fewer babies died, with 
perinatal mortality being 4.6/1000 vs.9.0/1000; p < 0.05. The difference was mainly 
due to better early detection of major malformations (detection rate 47%) and 
subsequent induced abortions. Twelve fetuses with major malformations were found 
in the screening group, which led to eleven induced abortions. In the control group, 
none of the women had induced abortions due to ultrasound findings (Saari-
Kemppainen et al 1990). 
  
The actual realised gross cost of one screening ultrasound examination,  was $86. The 
major cost items were lost working time cost (25%), staff (23 %), equipment (19%) 
and overhead costs (17%). The random sample revealed that the women spent 74 min 
travelling; 81% were working, more than half of whom used their working time for 
the ultrasound appointment. In the entire sample the average time spent at the 
outpatient department was 61 min. The actual time reserved for the appointment was 
22 min at the City Hospital and 30 min at the University Hospital. 
 
The cost of screening-induced advanced examinations and procedures was 16% of the 
total gross unit cost of $102. By adding the later obtained data of more numerous 
visits to a health center the unit cost became $ 114. (Leivo et al unpublished results). 
In the screening group there were more visits to the maternal health center (12.9 vs 
12.5, p <0.0001). 
  
The negative cost, i.e., the savings, of screening was due to less use of antenatal health 
services. Total outpatient visits were fewer in the screening group (mean 2.34 vs. 
2.59; p <0.0001), as were inpatient days (mean 2.32 vs. 2.51, p=0.15). The mean 
number of other antenatal ultrasound examinations was also smaller, at mean 1.14 
(excluding the screening ultrasound) vs. 1.80; p < 0.0001. The total negative unit cost 
calculated per screening ultrasound examination was $182, two-thirds of which was 
accounted for by the lower inpatient cost. 
 
The gross costs of avoiding one perinatal death were US$ 21 938, when the changes in 
the use of other health services were excluded. The ratio was US$ 19 096, when the 
savings from fewer outpatient visits were taken into account. Adding the savings from 
fewer inpatient stays, the ratio was US$ -7100, while also including the savings from 
fewer ultrasounds made it US$ -17 077. When also was added, the later obtained data 
of costs of more numerous visits to maternal health centers the ratio was  
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U$ -11 515.   
 
The University Hospital used 8 min longer per ultrasound examination and a more 
detailed pre-structured form for findings than the City Hospital. The malformation 
detection rate was better in the University than in the City Hospital (75% vs. 35%), 
and the gross unit cost for ultrasound was $124 in the former and $89 in the latter. The 
cost-effectiveness ratio by hospital was estimated as gross costs, (i.e., excluding the 
use of other health services) vs. induced abortions. This ratio was $28 005 in the 
University and $55 654 in the City Hospital. 
  
Even substantial changes in gross costs changed the screening cost-effectiveness ratio 
very little. By contrast, the cost-effectiveness ratio changed +19%, when the savings 
of antenatal inpatient days was changed by 5%. Changing the values of other savings 
items had only a marginal effect. 
 
6.2 Breast carcinoma screening (II) 
 
The relative risk of death from breast cancer among the invitees compared to those not 
invited  was 0.76 (95% confidence interval 0.53-1.09), which indicated a 24% 
protective effect due to screening which was not statistically significant (Hakama et al 
1997). The total undiscounted LYS in the sample of 89 893 invitees in 1987-1992 
were 56. 
 
In the base case, where the difference in cumulative relative breast cancer mortality 
between the screening and control group was estimated to remain constant after 5 
years following diagnosis, the total number of discounted life-years saved was 578. In 
1987-1992 the number of discounted life years saved was 46, i.e., 8.0% of the total 
life-years saved. In the second case, where the difference in cumulative relative breast 
cancer mortality between the groups was estimated to be constant after 7 years 
following diagnosis, the total number of discounted life years saved was 585. In the 
third case where the difference in cumulative relative breast cancer mortality between 
the groups was assumed to be constant after the end of  the screening in 1992, the total 
LYS was estimated to be 271. 
 
During 1987-89, 76,389 women entered the program, and on the assumption of a 90% 
participation rate in the re-screenings of 1990 to 1992, altogether 201,141 screening 
examinations were performed. The unit health care cost of screening (excluding 
further assessment) was between US$25 and US$45. This difference was mainly due 
to differences in the salary and social expenses cost. Taking into account the cost of 
assessment, the unit cost of screening was between US$28 and US$51. The screening 
unit’s higher unit cost of screening did not correlate with higher quality of screening, 
measured by the cancer detection rate (Leivo unpublished result). The unit cost 
difference reflects the actual resource cost, which differed from the market price of the 
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service. The high cost screening unit set the market price below the resource use cost, 
and subsidized the screening by other sources. (Leivo unpublished result).   
 
The unit cost of transportation (one-way) was US$3 (SD US$4) and the cost of time 
was US$4 (SD US$12). The average total time spent was 1 hour 12 minutes.   
 
The unit health care cost of surgery for false positives was  on average US$1,548. The 
cost of transportation was US$8 and the time cost US$267, resulting from the normal 
practice of giving one week’s sick-leave. 
 
The health-care saving per every new case of breast cancer due to early treatment was 
estimated to be US$2,091; transportation cost was US$20 and time cost US$325. 
 
The national ratio of carcinoma in situ ductal to total breast carcinomas was 1.54 
percentage units higher and the ratio of carcinoma in situ non-ductal to total breast 
carcinomas was 0.93 percentage units higher in the period 1990-94 compared to the 
period 1980-84 . The 1990-1994 figures were applied to the screening group. The cost 
of treating 72%  (Page et al 1982 ) of those new intraductal breast carcinomas and 
62% (Rosen et al 1978) of those new nonductal breast carcinoma in situ, which 
exceeded the proportion of equivalent carcinomas in situ to carcinomas in total 
estimated from the 1980-1984 data, was assumed to be the cost of the overtreatment 
of breast carcinoma in screening. Consequently, we estimated 10.1 (1.54 % * 907 * 72 
%) ca in situ ductal and  5.2 (0.93 % * 907 *62 %) ca in situ non-ductal to be due to 
over-diagnosis in the screening group.   
 
The total costs of the screening in the base case were US$11 million, i.e., US$14.3 
million per 100,000 participants, with 84% of the total cost consisting of the base 
mammography screening. Altogether 82% of the total costs were health care costs.   
 
The discounted LYS  per 1,000 screens was 3.2 in the base case. The cost per life-year 
saved was US$18,955 in the base case. 
 
In the univariate sensitivity analysis the C/E ratio was sensitive to changes in the 
number of life-years saved and to the  base cost of the mammography. However, the 
C/E ratio was not sensitive to changes in other cost items. 
 
Under different model assumptions the cost-effectiveness ranged from US$15,502 to 
US$40,308. The largest deviation caused by the change in costs, +30% compared to 
the base case, fell under assumption IV, i.e. when time cost was counted for all 
attendees irrespective of working status. The largest deviation caused by the change in 
effects, +123% compared to the base case, was under assumption IX, meaning when 
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the cumulative relative breast cancer mortality reduction was assumed to be constant 
after the end of screening (1992) in the study and control groups. (Table 6). 
 
6.3 Double-reading mammograms (III) 
 
The total number of cancers detected with the double and single reading was 290 and 
was 261.  The proportions of cancers detected by the second reader were closely 
similar in all three screening centers, with no statistically significant difference 
(p>0.1). Differences in possible consensus practice or in number of further assessment 
procedures had no meaningful effect on the proportion of cancers detected among the 
mammographs performed. 
 
Cancers detected by the second reader only were slightly smaller in size by 
mammography, but were larger by microscopy. These differences were not 
statistically significant. A significantly (p<0.05) higher ratio of carcinoma in situ was 
the causative pathology  in cancers detected only by the second reader (40% vs 17%). 
 
The incremental unit base cost of screening was US$ 6. The labor cost of the second 
radiologist was US$ 5. The rest were the allocated costs of  the additional office work, 
space and overhead costs. The incremental total base cost of screening was US$ 589 
570, representing 80% of the incremental total net cost of double reading.  
 
The incremental total cost of double reading was US$ 740 160, representing 13.0% of 
the total screening programme cost of US$ 5.5 million with the double reading 
strategy.  
 
Table 6 - Total costs (US$), effects and cost-effectiveness of breast cancer screening under various 
model assumptions
    Costs Effects C/E
I base case 10 956 115 578 18 955
II surgery cost only for clinically evaluated unnecessary false positives 9 241 836 578 15 989
III no overtreatment cost 10 737 529 578 18 577
IV time cost for all attendees; based on average salary of sample 14 260 234 578 24 672
V no transportation and time cost 8 959 890 578 15 502
VI discount rate 5% 10 302 932 431 23 905
VII no overtreatment, transportation and time cost, discount rate 5% 8 254 462 431 19 152
VIII difference in breast ca survival constant after 8 year from diagn. 10 923 341 585 18 672
in screening and no-screening groups   
IX difference in breast ca survival constant after end of screening 10 923 341 271 40 308
(1992) in screening and no-screening groups  
II According to a Finnish study, 30% of these operations should be classified as unnecessary, 
whereas the rest of the lesions have a small, but elevated risk of malignancy or might cover a
malignant lesion (Jahkola et al 1991)
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The incremental assessment procedures cost caused 27.2% of the total assessment-
procedures cost, and the incremental surgical procedures cost was 13.2% of total 
surgical-procedure cost. 
  
The cost per one cancer detected with a single reading was US$ 18 340 and with a 
double reading US$ 19 058. The incremental cost of an additional cancer found was 
US$ 25 523, i.e., a 39% higher cost per cancer found by the double compared to the 
single reading.   
 
The incremental C/E ratio varied from US$ 21 026 to US$ 34 744 in the different 
screening centers. The variation was mainly due to differences in the number of 
incremental cancers found in each screening center and partly due to differences in the 
number of assessment procedures performed.  
 
In the univariate sensitivity analysis the C/E ratio was clearly sensitive to the number 
of cancers detected and to health care cost of the base screening test. It was not 
sensitive to changes in other cost items. When only invasive cancers were included 
and carcinoma in situ cases were excluded, the C/E ratio was US$ 42 538. 
6.4 Helicobacter pylori screening (IV) 
 
The incremental health care cost per case under different multivariate model 
variations is given in Table 7. The cost per case, i.e. person invited for screening, was 
US$ 69 in screening and US$ 43 in the no-screening alternative in baseline case 
analysis. Thus, the incremental cost per case was US$ 26. Incremental cost per treated 
H pylori infection due to screening was US$ 412.  The incremental cost per case was 
highest in the group aged 15 years and lowest in the group aged 45 years, where the H 
pylori screening showed cost savings per case.  The incremental cost per case was  
US$ 38  when all disease probabilities were simultaneously changed to minimum 
values and US$ 15 when maximum values were used. 
 
In the probabilistic sensitivity analysis, the screening vs. no-screening values were: 
mean 68.7 vs. 43.1,  SD US$ 4.5 vs. 5.3, minimum values US$ 55 vs. US$ 27 and 
maximum values US$ 81 vs. US$ 63.    
 
In the univariate sensitivity analyses, the largest deviations were caused by changes in 
the estimated probability of H  pylori-caused gastric cancer (cost benefit range from 
US$ 24 to US$ 30) or gastric pre-malignant lesions (range from US$ 23 to US$ 31). 
The cost difference between the screening and no-screening alternatives was not 
sensitive to changes in the selected cost variables, notwithstanding the baseline cost of 
the screening test and the GP visit (Table 7). 
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Table 7. Incremental costs (US$ 1998/99) per case under selected 
model variations.   
Model US$ 
Multivariate analysis   
Baseline case 26
Age at screening 15 years 36
Age at screening 30 years 27
Age at screening 45 years -6
All Hp-related disease probabilities at minimum value 38
All Hp-related disease probabilities at maximum value 15
Base cost of screening +20% (Hp test + Gpvisit) 31
Univariate analysis   
Estimated lifetime probability of Hp-related cancer 0.005, if Hp+ 30
Estimated lifetime probability of Hp-related premalign 0.020, if Hp+ 31
Screening test specificity 0.98 20
Hp = Helicobacter pylori  
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VII DISCUSSION 
 
7.1. Material and methods 
 
7.1.1 Cost-effectiveness-analysis material and methods (I, II, 
III) 
 
In assessing screening programmes, process measures instead of direct outcome 
measures are often chosen. The choice of process measures causes more uncertainty to 
the economic evaluation of screening than the choice of final health output measures. 
In the present study the measure of cost-effectiveness was related to the final health 
output, i.e. life-years saved in the breast carcinoma screening study (II). In the double-
reading mammograms study (III) the measure of cost-effectiveness was incremental 
cost per additional cancer found. An additional case of cancer found is only an 
indirect measure of the life years saved. Due to missing data, the number of life-years 
saved could not serve as a measure of effectiveness. No published clinical trial study 
could be detected, where the number of life-years saved due to double -reading would 
have been estimated.  
 
It is noteworthy that the one-stage ultrasound screening (I) does not inevitably produce 
life-years saved, although it reduces perinatal mortality. It can even produce less life-
years. The cost of avoiding one perinatal death gives us the cost of the mainly 
psychological benefit of the mother being able to terminate the pregnancy instead of 
giving birth to a dead baby, a baby who would die immediately after the delivery or 
who would be severely malformed.  
 
Cost-effectiveness of the ultrasound screening (I) was strongly dependent on the rates 
of malformation detection and subsequent pregnancy termination. It was implicitly 
assumed that the perinatal mortality rates in the control and intervention groups would 
have been the same if no screening had taken place. Although the patients were 
randomly assigned to the groups, this assumption may not be justified. In the 
screening group 19 fewer babies died, with perinatal mortality being 4.6/1000 vs. 
9.0/1000; p<0.05. However, the number of major malformations found was 12 and the 
number of ultrasound induced abortions was only 11. In this aspect, the choice of cost 
per major malformation found  would have been more unambiguous measure of cost-
effectiveness.  
 
The ultrasound study (I) effectiveness data were considered representative being from 
a randomized, controlled trial, which included a large sample, lost only four women 
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during follow-up, and had complete mortality data, all of which led to accuracy in the 
estimation of effectiveness.  
The breast carcinoma study (II) effectiveness data were from a nationwide population-
based screening programme from 1987 to 1992 and from an estimation model using 
parameters based on published studies and national cancer statistics from 1993 to 
2020. Finland was the first country to introduce nationwide breast cancer screening as 
a public health policy; this was in 1987. The program was expanded rapidly, and thus 
the follow-up of the effect could be evaluated only to the end of 1992, because the 
controls were also gradually being screened (Hakama et al 1997). Consequently, only 
8% of the total LYS emerged during the actual follow-up period in our base-case 
estimation.  That,  on average, the follow-up was four years and there was a 
statistically non-significant effect, reduced markedly the possibility of estimating the 
exact number of life-years saved. The effectiveness data were subject to considerable 
limitations due to the time horizon. As a consequence, the economic evaluation was 
drawn on published articles and methods of extrapolation, i.e. modeling. 
 
The effectiveness data of double-reading mammograms study (III) were original 
retrospective data. They were considered representative, being community-based and 
comprising 15% of all mammographs read in Finland during a 5-year period within a 
nationwide screening program. We had access to the original gradings of the first and 
the second reader, which enabled us to estimate the incremental effectiveness of the 
double-reading accurately.  The fact that the second reader had access to the results of 
the first reader’s results means that the incremental nature of the evaluation does not 
fit the definition of independence. However, our study evaluates the incremental cost-
effectiveness of the actually used double reading strategy in Finland, i.e., a strategy 
where the double reading was not all blind. 
 
The costs were evaluated from the societal perspective, i.e. including the health care 
and non-health care and time costs of the screening intervention. In the present studies 
the non-health care cost was the cost of transportation. Time costs did not include the 
time cost of possible accompanying persons at the screening. This cost was estimated 
as insignificant due to the age of screenees. The cost of lost home work was only 
included in part of the sensitivity analyses, but in no base line cases. The valuation 
principles of the opportunity cost of unpaid inputs are under debate among health 
economists (Posnett et al 1996) and we chose to  exclude the cost of lost home work 
in base line cases, since that is the most common practice in current published cost-
effectiveness analyses. However, this practice does not follow the principle of broad 
societal perspective. Additionally, following the guidelines by Gold et al (1996) and 
common scientific practice, productivity costs were not included in the cost 
accounting, although contrary opinions exist among health economists (Brouwer 
1997). The valuation of extremely intangible and ambiguous costs of screening, as the 
cost of anxiety, reassurance and information per se were not either included in the 
analyses. The inclusion of cost of lost home work, productivity cost and costs of 
anxiety would have increased the present cost-effectiveness ratios. The inclusion of 
the costs of reassurance and information per se would have decreased these ratios. 
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The cost savings due to terminating a life were not included in the cost-effectiveness 
analysis of ultrasound screening in pregnancy. This was due to the short time horizon 
of the analysis. Although morally difficult, a longer time horizon and subsequent 
inclusion of the saved resources associated with the termination of pregnancy would 
theoretically have produced more detailed estimates for the economic evaluation. 
 
Actual resource use costs where used, when evaluating the base cost of screenings and 
most of the screening induced further examinations. This method sharpens the cost 
estimation significantly, as Finland is a Nordic welfare state, where the health care is 
mainly publicly financed and the competition among producers is scarce and often 
distorted. The pricing of products or services is seldomly resource-based. The actual 
resource use costs were obtained from the screening organizations’ internal 
accounting. Various adjustments were made in order to standardize the different 
accounting methods. This was done in co-operation with the organizations’ 
accounting managers in order to obtain all the data behind the public figures and thus 
to produce the most reliable resource use estimates.  
 
The antenatal health care (I) is traditionally not based on competition between 
different producers.   Thus we used the internal accounting data from the two trial 
public hospitals, where the screening took place. At the time of the cost estimation of 
ultrasound screening the accounting principles in the two hospitals did not 
comprehensively include  many major cost items, e.g. the rent, overhead, depreciation 
or capital costs. These were adjusted for in our study estimates. Compared to most 
Finnish health care interventions the mammography screening (II, III) has been a 
competition between different producers at least in some municipalities. However, the 
quality of the cost accounting methods in the different organizations was variable, and 
thus adjustments were made to standardize the different accounting methods. This 
sharpened the cost estimation significantly. 
 
Our studies did not include the quality adjusting of life-years gained. In the ultrasound 
study the measure of cost-effectiveness was cost per avoided perinatal death, which as 
such can not be quality-adjusted. The  quality-adjusted life-years saved of 
mammography screening need to be evaluated in future studies.   
 
  
7.1.2 Cost-benefit – analysis material and methods (IV) 
 
 
Cost – benefit analysis using computer-based decision tree was chosen for the method 
for economic evaluation of H pylori screening, as for the time being no randomized 
controlled trial data, or other clinical data exist for the evaluation of life-years saved 
due to H pylori screening. Due to the time horizon, the available Vammala 
Helicobacter pylori trial data was not suitable for the evaluation of effects measured in 
life-years saved. In addition, the study was conducted to answer a specific question by 
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the clinicians and decision makers concerning the possible  health care cost savings 
due to nationwide H pylori screening programme. Few primary studies will be able to 
collect direct data measuring effects along the entire cascade of events from 
intervention to health outcome. Modeling must often be used to combine information 
from different data sources. (Gold et al 1996). 
 
Cost – benefit analysis measures costs and benefits in monetary terms. In theory this 
implies that all the consequences of an intervention would be expressed in monetary 
terms. In practice, cost-benefit analyses usually amount to a comparison of those costs 
and benefits that can be easily expressed in money terms (Drummond et al 1987). In 
the present study productivity costs and the intangible costs of a more diffuse nature, 
such as the value of death or the value of anxiety, reassurance or information per se 
were excluded from the analysis. Thus the willingness to pay of the individuals who 
benefit from the programme was not estimated. This method is recommended by e.g. 
Johannesson et al. (1996), but in the present study our aim was to include only 
unambiguous monetary costs in the analysis. 
  
The non-health care and time costs and benefits were not included in the present 
model. Their inclusion would have increased the uncertainty of the outcome of the 
model. Unfortunately, their exclusion makes the comparison between the Helicobacter 
pylori – study (IV) and the other studies (I, II, III) more difficult. This cost-benefit 
analysis is a first-line approach taking into account only the direct financial 
implications of the H pylori screening. However, screening also produces better 
health. The cost-effectiveness, life-years saved and quality-adjusted life years saved 
from broad societal perspective need to be evaluated in future studies. 
 
The decision tree model was planned keeping in mind the complexity of the problem 
and the clarity of the model. For the sake of clarity, the H pylori - related disease 
probabilities were presented as net probabilities. The probability of a H pylori positive 
patient to develop a H pylori-related disease due to infection was presented instead of 
distinct probabilities of H pylori positive and negative patients to develop the disease. 
Certain cost-causing events, e.g., costs prior to the H pylori – related disease 
diagnosis, were not represented as nodes in the decision tree, but included directly in 
the aggregated cost estimates. The estimated lifetime risks of H pylori-related diseases 
were disease-specific in the model, i.e., the possibility of successive H pylori-related 
diagnoses was not included in the model. Thus the probability of no clinical 
symptoms may be underestimated. Possible re-infection or spontaneous cure were also 
excluded. All these simplifications undoubtedly impact on the outcome of the model.  
 
In the decision model structure after participation the following branch was infected / 
not infected, and the following branches sensitive/ not sensitive test and specific/ not 
specific test. This may cause slight incorrectness of the outcome of the model. A more 
accurate option would possibly have been to plan the model structure by using branch 
positive test / not positive test and the following branches true positive/ false positive 
and true negative / false negative.  
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Probability estimates for screening – related variables were considered representative 
being based on realised pilot screening programme in Finland. However, probabilities 
may vary markedly across countries (Stone et al 1998). The sensitivity and specificity 
of the Helicobacter pylori screening test were obtained from the Vammala 
Helicobacter pylori trial data. Unfortunately, the confidence intervals of sensitivities 
and specificities were not represented. However, these both were included in the 
sensitivity analyses to estimate the impact of possible uncertainty caused by them. The 
simplifying assumptions of no third treatment failure and 100% sensitivity and 
specificity of the screening retests were estimated to have little impact on the outcome 
due to relatively small number of cases. 
 
Probability estimates for H pylori-related disease variables were obtained from 
selected references in the literature. Because some of the H pylori-related conditions 
and consequences are little studied, all probabilities could not be based on solid 
existing evidence thus causing possible uncertainty in the baseline outcome of the 
model. Consequently, in some aspects the probability estimates were based on expert 
opinion, which can be affected by various biases. (Poses et al 1988). Attempts to 
compensate for this, include carrying out several sensitivity analyses and using 
relatively wide variable ranges in these analyses.  
 
The evidence for potential negative effects of curing Helicobacter pylori is 
controversial. We have not considered the potential adverse effects of wide use of 
antibiotic therapy leading to bacterial resistance.  In addition the model does not 
consider the possible effect of the cure of H pylori infection on the development of 
reflux esophagitis and the primary adenocarcinoma of the esophagus (Labenz et al 
1997).  These choices may cause underestimation of the outcome of the model. 
 
7.1.3 Valuation and discounting methods (I, II, III, IV) 
 
The year of price level varied from 1990 (I) to 1995 (II, III) to 1998/99 (IV) in the 
present studies. It is noteworthy that the early years’ cost- effectiveness ratios would 
be higher at the later years’ price levels.   
 
There is broad agreement that in cost-effectiveness analyses all future costs and health 
consequences should be stated in terms of their present value, i.e., discounted. Only 
then will the interventions’ cost-effectiveness ratios be appropriately adjusted for the 
decision-maker’s time preference for present over future outcomes (Gold et al 1996, 
Drummond et al 1987). A discount rate of 3% for costs and effects was used in the 
base case analyses, because given currently available economic data, 3% is 
recommended as the most appropriate real riskless discount rate for economic 
analyses by the Panel on Cost-effectiveness in Health and Medicine appointed by the 
U.S. Public Health Service in 1993 (Gold et al 1996). A discount rate of 5 % for costs 
and effects would have increased the cost-effectiveness and the cost-benefit of 
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screenings. A smaller discount rate for the effects than costs would have shown the 
cost-effectiveness to be more favourable to screening than the current analyses.  
 
7.2 Ultrasound screening in pregnancy  (I) 
 
The earlier economic evaluations of screening ultrasound (Ewigman et al 1993, 
Persson et al 1983, Temmermann et al 1991, Bakketeig et al 1984), which reported the 
unit cost of screening ultrasound being between $23 and $540 (the latter including two 
ultrasounds) are difficult to compare with our study, because the studies did not 
estimate the effectiveness. In addition, in the Stockholm trial (Waldenström et al 
1988) patients with an indication for ultrasound where excluded, and  the Norwegian 
trials (Bakketeig et al 1984) had small population sizes. It is worth  noting, that these 
studies did not report the cost-accounting principles, which makes also the 
comparison of the unit cost difficult. The use of other antenatal health services has 
been very variable in other studies from more use to less use (Persson et al 1983, 
Jörgensen 1992, Backe et al 1990). The use of other antenatal health services is most 
probably different in different health care settings, and as such must be nation-
specificically estimated. 
 
DeVore (1994) reported the cost per detected malformed fetus as $29 533 in tertiary 
centers and $115 575 in non-tertiary centers, depending on the different diagnostic 
rate of malformed fetuses in different types of centers. Similar to the present study the 
cost-effectiveness ratio was better in the centers, where the detection rate for 
anomalies was highest. It is noteworthy that in the deVore (1994) study the measure of 
cost-effectiveness was the cost per detected malformed fetus, which decreases the C/E 
ratio compared to our study. DeVore (1994) used the effectiveness data from RADIUS 
study. In the RADIUS trial (Ewigman et al 1993) around 60% of all those registered 
where excluded, based on various risk-factors, which can markedly change the 
outcome of the trial, whereas the Helsinki trial was population-based.  In the Helsinki 
ultrasound Trial the detection rate of major malformations was 40% in the screened 
group overall. The RADIUS study had a detection rate of 16.6% before the 24th week, 
the total detection rate being 35%. The different C/E ratios reflect also the different 
methods of organisation, i.e., the RADIUS - study was done in the United States, the 
ultrasound screening was done twice and it was performed by obstetricians. These 
differences  increase the C/E ratio compared to our study. 
  
It is of note, that even though the present analysis is based on a randomized controlled 
trial, the decrease in perinatal mortality was substantially higher than the number of 
ultrasound induced abortions (19 vs. 11) in the screening group. This may cause 
uncertainty about the effectiveness, which is not totally indicated in the present study.      
 
I consider the gross cost-effectiveness ratio (US$ 21 938 per one avoided perinatal 
death) , i.e., excluding the changes in the use of other health services as the most 
unambiguous outcome of the present study. However, the screening was cost-saving, 
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when all antenatal use of other health services were included. It is noteworthy that the 
cost-effectiveness of the ultrasound screening was strongly dependent on the negative 
cost of inpatient days. However, the difference in inpatient days between the groups 
was not statistically significant. Any difference between the inpatient days of the two 
groups is possibly therefore a result of chance, and the cost-effectiveness findings 
concerning inpatient days uncertain.  
7.3 Breast carcinoma screening (II) 
 
Comparison of our results with other breast cancer C/E studies is difficult, mainly due 
to different methodological principles, but also due to national differences concerning 
breast cancer incidence, survival and health care organisation.  The year of estimation 
also has an effect on the cost per life-year saved due to inflation. Previously published 
C/E ratios are given in Table 1. 
 
Studies which have reported unclearly the LYS (Gerard et al 1990, Forsyth 1988) or 
have estimated the LYS for a relatively short period after screening are difficult to 
compare with our study (Australian Health Minister’s Advisory Council 1990, Clarke 
et al 1991, Forrest 1987, U.S. Congress, Office of Technology Assessment 1987, 
Kattlove et al 1995, Hristova et al 1996). Gerard et al (1990),  Forsyth (1988), Okubo 
et al (1991), Kattlove et al (1995), and Hristova et al (1996) did not discount the LYS, 
which led to considerable underestimations of the cost of LYS.   
 
The majority of previous studies have used a 5% discount rate compared to our 3% 
(Australian Health Minister’s Advisory Council 1990, Clarke et al 1991, Forrest 1987, 
U.S. Congress, Office of Technology Assessment 1987, Eddy 1989, Brown 1992, van 
der Maas et al 1989, de Koning et al 1991, Hall et al 1992, Lindfors et al 1995, van 
Ineveld et al 1993). To facilitate the comparisons we estimated the cost-effectiveness 
of the base case also with a 5% discount rate, which resulted in a 26% higher cost-
effectiveness ratio compared to the base case. Thus, a base case discount rate of 5% in 
the present study would have increased the cost per life-year saved markedly. 
 
Most authors have estimated the breast cancer mortality reduction to be over 28% 
(Forrest 1987, U.S. Congress, Office of Technology Assessment 1987, van der Maas 
et al 1989, de Koning et al 1991, Lindfors et al 1995, van Ineveld et al 1993, Hristova 
et al 1996, Norum 1999). Due to this our estimation of the cost per life year saved is 
higher than in other studies. 
 
The cost-effectiveness of breast cancer screening is very sensitive to the LYS, and 
thus to the methods used in estimating the LYS. In 1987, Finland became the first 
country to introduce nationwide breast carcinoma screening as a public health policy. 
The program was expanded rapidly, and thus the follow-up of the effect could be 
evaluated only to the end of 1992, because the controls were also gradually being 
screened. Consequently, only 8 % of the total LYS emerged during the actual follow-
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up period in our base-case estimation. The fact that, on average the follow-up was 4 
years and was a statistically non-significant effect, reduced markedly the possibility of 
estimating the exact number of LYS. According to most studies based on clinical 
trials or case-control studies, a major proportion of the deaths prevented will be seen 
after the first 4 years. However, the size and length of the effect, as well as the 
screening schemes, are variable. The LYS depend crucially on whether early or late 
deaths are prevented, and in this regard most published trials have relatively short 
follow-up times.  
 
The majority of published trials and meta-analyses have shown screening 
mammography to reduce breast carcinoma mortality among women older than 50 
years.  However, the Canadian, Edinburgh and Finnish trials report either no effect or 
a statistically insignificant effect (Miller et al 1992, Kerlikowske et al 1995, Hakama 
et al 1997, Roberts et al 1990, Alexander 1997). Meta-analyses by Gotzshe et al 
(2000) reported mammography screening not to reduce breast cancer mortality. If the 
truth about mammography lies close to Gotzshe, the cost/LYS would be much higher 
than in the present study base case, or even the present study maximum case, derived 
from the sensitivity analysis. In the extreme case, where effectiveness would be zero, 
the cost – effectiveness would be infinite. 
 
The cost-effectiveness of breast cancer screening is also sensitive to the base cost of 
screening. The base cost of screening in Finland (US$ 42), even though contrary to 
most published studies (U.S. Congress, Office of Technology Assessment 1987, Eddy 
1989, Brown 1992, Okubo et al 1991, Kattlove et al 1995, Hall et al 1992, Lindfors et 
al 1995, van Ineveld et al 1993, Hristova et al 1996 ) the non-health care and time 
costs were included, was only average. 
 
The C/E ratio in our study estimated the cost-effectiveness of the national program 
during the period 1987-1992. The  C/E ratios, including different age-groups, 
screening intervals, and quality-adjusted life-years, need to be evaluated in future 
studies. The quality-adjustment would increase the cost per LYS, in the previous 
studies the multiple has been 1.01-2.27 (Australian Health Minister’s Advisory 
Council 1990, Clarke et al 1991, Forrest 1987, de Koning et al 1991, Hall et al 1992, 
Hristova et al 1996). 
 
Methodologically our study is quite comparable with the studies of the U.S. Congress, 
Office of Technology Assessment (1987), de Koning et al (1991) and van Ineveld et al 
(1993). In the OTA study the screening was annual, and both screening costs and 
effects were evaluated for the years 1990 to 2020, after which no costs or effects were 
estimated. The discount rate was 5%. These assumptions increase the cost per life-
year saved compared to our base case estimation. De koning et al (1991) and van 
Ineveld et al (1993) have used the same computer model when estimating cost-
effectiveness. Van Ineveld et al (1993) has simulated the cost-effectiveness in the 
United Kingdom, the Netherlands, France and Spain. In Spain the incidence and 
survival rates are relatively similar to those in Finland, and the estimated discounted 
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life-years saved per 1,000 screens (3.9 vs.3.2) and cost per life year saved (US$15,326 
vs. US$18,955) were similar.  
 
The inaccurancy in the estimation of life-years saved is mainly due to the fact that the 
cost of breast carcinoma mammographic screening per life-years saved  varied under 
different model assumptions in the present study. Taking into account the range from 
US$ 15 502 to US$ 40 308, it can be concluded that the base case estimation of US$ 
18 955 represents more the low than high estimate of the cost - effectiveness ratio.       
 
7.4 Double-reading mammograms  (III) 
 
In the present study a double reading was more effective in breast cancer detection 
than a single reading. These findings confirmed those reported elsewhere (Anttinen et 
al 1993, Anderson et al 1994, Brown et al 1996, Ciatto et al 1995, Warren et al 1995, 
Brown et aal 1996, Blanks et al 1998).   
 
Brown et al (1996) found  saving per additional breast cancer detected of GBP 485 
(US$ 766) when comparing consensus double with non-consensus single readings, 
and the incremental cost per additional cancer detected was GBP 1926 (US$ 3043) 
when comparing non-consensus double to non-consensus single reading. They 
estimated that the incremental unit health care cost of the second reading would range 
from GBP 0.62 to 0.69 (US$ 0.98 to 1.09), based on the observation that a total of 1 
980 images were read in 678 minutes. This exceeds the Finnish reading speed 
markedly. In addition, we have included in our calculations the total working time 
paid for, not just the effective performance time. We also included the saving due to 
the early detection included in the majority of the breast cancer cost-effectiveness 
studies. Unlike Brown et al (1996), we focused solely on the cost-effectiveness of the 
double compared to the single reading, and assumed a strategy of single reading with 
consensus. A single reading strategy does not inevitably exclude consensus reading. 
 
The biological significance of carcinoma in situ in breast cancers detected by 
screening is uncertain. A higher incidence of carcinoma in situ in the double-reading 
than in the single reading screening strategy may be a sign of over-diagnosis or 
earliness of diagnosis (Wright et al 1995, Ernster et al 1996). If the carcinoma in situ 
lesions were due to over-diagnosis, than there was in fact a higher incremental cost for 
additional cancer found by the double reading strategy. If  all the additional carcinoma 
in situ are considered  over-diagnosis, the base case incremental C/E ratio would be 
nearly twice as high (25 523 US$).  
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7.5 Helicobacter pylori screening (IV) 
 
Comparison of the present study with previous studies is limited due to two main 
factors. Firstly, no previous study has represented the economic evaluation of H pylori 
screening taking into account all the main H pylori-related diseases. Secondly, the 
previous economic analyses have been carried out as cost-effectiveness instead of 
cost-benefit analysis.  
 
Parsonnet et al (1996) and Fendrick et al (1999) have estimated the cost-effectiveness 
of H pylori screening taking into account one H pylori-related disease, gastric cancer. 
Compared to the present study the main difference in the cost accounting methods of 
Parsonnet et al (1996) was, that they included the future resource use costs in added 
years of life, and of Fendrick et al (1999) was, that they did not include the treatment 
cost of gastric cancer in their baseline analyses. Both of these increase the cost-
effectiveness of screening. There is a longstanding theoretical controversy about 
including future resource use costs for unrelated illness in added years of life. In 
addition, there are many practical difficulties in including these costs (Gold et al 
1996).  
 
However, our results, like those of Parsonnet et al (1996) found that cost –
effectiveness or cost- benefit was less favorable, if screening was performed at 
younger ages.  
 
It is noteworthy, that to date there is not much data available from definitive studies 
quantifying the risk of H pylori-related diseases. Consequently, all probabilities could 
not be based on solid existing evidence thus causing possible uncertainty about the 
outcome of the model. Attempts to compensate for this included carrying out several 
sensitivity analyses and using relatively wide ranges in these analyses. However, the 
choice of variable range is nevertheless subject to discussion as there is little direct 
evidence that eradication of H pylori will reduce the risk of Hp-related diseases.    
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VIII SUMMARY AND CONCLUSIONS 
 
 
The purpose of the present study was to conduct an economic evaluation of two 
nationwide Finnish screening programmes, and  one pilot Finnish screening 
programme intended for nationwide use. 
 
Cost –effectiveness analysis was used for the evaluation of ultrasound screening in 
pregnancy, breast carcinoma screening and double-reading mammograms practice 
within breast carcinoma screening. The outcome measures were the cost per  avoided 
perinatal death due to ultrasound screening, cost per life-year saved due to breast 
cancer screening and incremental cost per additional cancer found due to double 
reading mammograms. Cost-benefit analysis was used for the evaluation of 
Helicobacter pylori screening using a computer-based decision tree. The outcome 
measure was the incremental cost per screenee.  
 
The effectiveness data of the ultrasound screening came  from the Helsinki 
randomised ultrasound trial comprising a trial population of 9310 pregnant women. 
The mammography screening effectiveness data came from Finnish nationwide 
population-based screening programme, comprising  90 000 invitees and 69 000 
controls. The data was completed with an estimation model. The double-reading 
mammograms effectiveness data were originally obtained from three Finnish 
screening centers, comprising 95 000 mammograms performed during 1990-
1995.Probability estimates for screening-related variables were obtained from the 
Vammala Helicobacter pylori pilot screening study comprising 5300 screenees. 
Probability estimates for Helicobacter pylori related disease variables were obtained 
from published reports and national statistics.  
 
Health care, non-health care and time costs were included in the cost-effectiveness 
analyses, only health care costs were included in the cost-benefit analysis. Cost-
accounting data were obtained from internal accounts of screening units, published 
studies, national statistics, health market sources and a questionnaire completed by a 
sample of 500 women at the ultrasound screening and by a sample of 1400 women at 
the mammography screening.  
 
The discount rate was 3%. Several univariate and multivariate sensitivity analysis 
were performed to reveal the robustness of the results to changes in key variables. 
 
The cost per  avoided perinatal death was US$ 21 938, when changes in the antenatal 
use of other health services were excluded. The screening became cost-saving when 
antenatal use of other health services was included in the calculations. It is noteworthy 
that the cost-effectiveness of the ultrasound screening was strongly dependent on the 
savings from fewer inpatient days. The difference in inpatient days between the 
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groups was not statistically significant and the cost-effectiveness findings concerning 
inpatient days uncertain. However, the present study suggests that longer ultrasound 
examination time and more numerous advanced examinations are rewarded by a better 
cost-effectiveness ratio. This indicates that high quality screening is of extreme 
importance, not only from ethical, but also from a cost-effectiviness perspective. The 
second trimester ultrasound screening during pregnancy can be considered justifiable. 
It is of note that the information per se which was not accounted for in the present 
study is also of major utility to the pregnant women. Special care has to be taken , that 
the women are well informed about the screening, and that the principle of self-
determination concerning screening and possible screening induced abortions is 
strictly respected.      
 
In breast cancer mammography screening the cost per life-year saved was US$18 955 
in the base case, ranging from US$15 502 to US$ 40 308 per life-year saved under 
different model assumptions.  The inaccurancy in the estimation of life-years saved 
was mainly due to the variation of the outcome under different model assumptions. 
The  base line case should be regarded as being towards the lower rather than higher 
end of estimates of the cost-effectiveness of breast cancer screening. The cost-
effectiveness is strongly dependent on the estimated effectiveness, i.e. number of life-
years saved. A major controversy still exists in the scientific community over the 
amount of effectiveness of mammography screening in the prevention of mortality. 
Some researchers have reported mammography screening not to be effective. If this is 
the case, the possible range of cost/ life-year saved is much wider than in the present 
study.  To conclude, mammography screening is a high-cost intervention with to some 
extent uncertain effectiveness. Nevertheless, in the female population, breast cancer is 
the most common cancer, with substantial mortality irrespective of modern 
treatments, making decision making about mammography screening morally very 
difficult. 
 
In double-reading mammograms the cost per additional cancer found was US$ 26 
000. The incremental cost per cancer found was 39% higher with double reading 
compared to  single reading. Double-reading found 10% of all the cancers. A 
significantly higher ratio of carcinoma in situ was the causative pathology in cancers 
detected only by the second reader. These results suggest that double-reading 
mammograms is more effective, but also markedly costlier than single reading. 
Decision-maker could consider allocating the resources to other use within breast 
cancer screening intervention or other interventions.      
 
The  H pylori screening resulted in an extra cost of  US$ 19 per screenee in the base 
case of the age group 15-45 years old. The incremental cost per screenee was highest 
in the 15 years’ age group and lowest in the 45 years’ age group. These results are 
subject to considerable uncertainty due to the lack of published clinical data. The 
present results suggest that the Helicobacter pylori screening is not a cost saving 
intervention, but that the incremental cost of H pylori screening may be surprisingly 
low. Further pathophysiological and evaluative studies in the area are encouraged. In 
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the 15-45-years-old population the possible screening should be targeted at the older 
cohorts.  
 
The use of economic evaluation when making decisions about the broad allocation of 
resources requires comparisons of a wide range of interventions. At present only a few 
evaluations of screening, and respectively of other health interventions, are available. 
Antenatal screening and screening in child counseling  clinic comprises a major part 
of the screening as a whole in Finland. It is noteworthy  that very few of these 
screening procedures are evidence-based or have been subject to economic evaluation. 
Additionally, the screening in child counseling clinic comprises of many 
interventions, which are not formally structured or verified. In this sector the need for 
screening for social and psychological disorders is growing (Appendix 1,2).  
Screening for these kinds of disorders is possible, but  new intervention strategies with 
structured process forms suitable for first-line and continuous evaluation are needed. 
 
Economic evaluation of screening intervention should be a continuous process 
alongside with  the intervention. One of the key difficulties in the present studies was, 
that the economic evaluation was not considered as a part of the screening process, but 
the need for it became evident to the decision-makers only many years after the 
beginning of trials.         
 
For the time being, cost accounting data and methods in the Finnish health care sector 
are of variable quality. Many  researchers have emphasized the fact that the health 
care cost estimates based on prices are currently mainly not resource-based. Thus, 
without adjustments they do not serve as a reliable basis for either evaluative studies 
or competitive markets. It is of utmost importance to develop the cost accounting 
methods in the public health care in Finland.  
 
In order to make comparisons, standardization of the evaluative methods is essential. 
To facilitate the allocation of scarce resources, the main principles concerning e.g., the 
rate of discounting, the methods for valuating health care costs in the absence of 
resource use cost and the methods of valuating time should be agreed upon. In the 
future research resources should be allocated for the development of Finnish standards 
for the conduct of economic evaluations. 
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APPENDIX 1. CURRENT SCREENING PROGRAMMES 
IN FINLAND 
 
1. ANTENATAL SCREENING TEST DISEASE 
blood pressure pregnancy-induced hypertonia 
pre-eclampsia 
urine albumin pre-eclampsia 
urine tract infection 
urine glucose gestational diabetes 
haemoglobin anemia of the mother 
blood-group antibodies anemia of the fetus 
serum sample for developmental 
abnormalities screening (b-HCG, PAPP-
A, AFP) 
21-trisomia 
meningomyelocele 
congenital nephrosis 
serum sample for infection screening syfilis 
hepatitis B 
HIV 
ultrasound  
13.-14. or 16.-18. gestational week 
structural malformations 
21- trisomia 
twin pregnancies 
dating of the pregnancy 
placental biopsy or amniocentesis 
(offered only for over 39-years-old 
women) 
chromosomal abnormalities 
clinical investigation by midwife 
(palpation, measuring of the uterus) 
fetus growth abnormalities 
abnormalities of the amount of amnion 
fluid 
abnormalities of the fetus position 
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2. PERINATAL SCREENING TEST  DISEASE 
placental serum tyrotropin  hypotyreosis 
clinical examination by midwife and 
pediatrician 
see below, 3. 
 
 
3. SCREENING TEST IN CHILD  DISEASE 
GUIDANCE CLINIC     
clinical examinations by nurse and GP 
• sight, lamp test 
• hearing, otoscopic examination 
 
• growth 
• weight 
• circumference of the head 
• physical neurological tests 
 
• psychomotor developmental tests 
 
• congestive developmental tests 
 
• physical testes examination 
 
• physical hip examination 
• physical cardiac examination, 
including blood pressure 
 
• vision disabilities, squinting 
• hearing disabilities, chronic 
middle ear infections 
• general pediatric diseases 
• general pediatric diseases 
• hydrocephalus 
• neurological diseases and 
developmental disorders 
 
• neurological diseases, 
psychomotor developmental 
disorders 
• neurological diseases, congestive 
developmental disorders 
• undescended testes, retractile 
testes 
• congenital dislocation of the hip 
• congenital heart disease 
 
 
 
 
 
 
 64
 
4. SCREENING TEST IN DEFENSIVE DISEASE 
ARMED FORCES 
formulated question sheet mental diseases 
(symptoms of) all somatic diseases 
height and weight overweight 
vision vision disabilites 
hearing, including otoscopic examination hearing disabilities, 
middle ear perforations 
physical cardiac examination, including 
blood pressure 
heart diseases 
physical stomach and gastroinguinal   
examination 
hernias 
physical skin examination pigment lesions susceptible to chafing 
physical leg examination structural deformities 
 
physical back examination structural deformities 
testes not defined 
 
5. CANCER SCREENING TEST  DISEASE 
cervical pap-smear cervical cancer 
mammography breast cancer 
 
 
References: Hiilesmaa et al 2000, Viisainen 1999, Leinikki et al 2000, Simell et al 
1997, Yleislääkärin käsikirja 1994, Lääkärintarkastusohje 1997, Teppo et al 2000.
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APPENDIX 2. PROPOSED SCREENING PROGRAMMES 
IN FINLAND 
 
SCREENING   PROPOSED  DISEASE   PILOT   
TYPE   SCREENING      PHASE 
   TEST 
Prenatal screening • serum-toxoplasma 
• serum-CMV 
toxoplasmosis 
cytomegalovirus infection 
x 
 
Child counseling 
clinic screening 
• not defined 
 
• electronic hearing 
test 
psychological or 
behavioural disorders 
severely impaired 
hearing disability 
 
Cancer screening • papillomavirustest 
 
• serum-PSA 
 
• feces occult blood 
 
• FSA (foetal 
sulphoglyco-
protein antigen) 
 
• serum-
pepsinogen1 
 
• lung computer 
tomography  
targeted cervical cancer 
screening 
prostate cancer 
 
colorectal cancer 
 
 stomach cancer 
 
 
 
stomach cancer 
 
 
lung cancer 
x 
 
x 
 
 
 
  
Infection screening • urine-chlamydia 
• serum 
helicobacter 
antibodies 
veneral chlamydia infection 
helicobacter pylori infection 
 
x 
Targeted screening 
• narcomanes 
 
• BRCA1/2 
 
• HIV, hepatitis 
A,B,C- antibodies 
• mammography 
 
 
HIV, hepatitis A, B, C 
 
breast cancer 
 
 
 
x 
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genedisorder 
• FAP-
HNPCC-
families 
• asbestos-
patients 
• colonoscopy 
 
 
• lung CT 
tomography 
 
colorectal cancer 
 
 
lung cancer 
 
x 
Genetic screening • serum-AGU-
gene- disorder 
• serum-INCL-
gene-disorder 
• serum-fragile X-
gene-disorder 
aspartylglucosaminuria 
 
infantile neuronal 
seroidlipofuscinos 
fragile X - syndrome 
 
 
 
 
x 
  
References: Hiilesmaa et al 2000, Leinikki et al 2000, Teppo et al 2000, Saarelma et 
al 2000, Robinson 1998. 
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